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Abstract 
Hereditary breast and ovarian cancer (HBOCs) accounts for about 10% of 
all breast cancers and BRCA1 and BRCA2 are the most prevalent genes associated 
to this pathology. They play a role in the maintenance of genome stability, 
particularly in the homologous recombination (HR) pathway for double-strand 
DNA breaks repair (DSBR). BRCA1/BRCA2 germline mutations dramatically 
escalate the risk of developing HBOCs by up to 20 fold. Therefore, testing for 
BRCA gene mutations is important to improve the clinical management of high-
risk patients and of their mutation-carrier family members. Here is reported the 
BRCA1/BRCA2 molecular screening of 300 patients with early-onset breast cancer 
(“under forty”), and/or with positive family history, carried out by using a next-
generation sequencing (NGS)-based approach, in order to identify mutation 
carriers. In particular, all the BRCA1/BRCA2 coding regions were amplified by 
multiplex PCRs, using specific sequence tags able to univocally identify each 
patient. In this way, we were able to simultaneously analyze up to 60 different 
samples in a single NGS run. After sequence data analysis, 24 known 
BRCA1/BRCA2 predisposing mutations were identified in 27 unrelated patients. 
About 12.5% of analyzed patients, including some males, carried a 
causative mutation. Several novel variants were also identified: double mutations, 
which include 1 nonsense mutation in the BRCA1 gene thereby causing a 
premature stop codon; 2 synonymous variants, 1 missense variant predicted not to 
have clinical significance, and 1 missense variant predicted to be deleterious. In 
addition, 2 novel possibly pathogenetic variants were also identified and specific 
functional studies were performed to assess their role. The first is a splice variant 
for which bioinformatic predictions, performed with both Human Splice Finder 
and NetGene2 tools, suggested a possible deleterious effect, since it could cause 
the loss of a canonic donor splice site of a BRCA1 intron. This was experimentally 
demonstrated on the HBOC patient cDNA by PCR amplifications and enzymatic 
digestion. The other is a missense variant located on the BRCA2 DNA-binding 
site that could impair the BRCA2 DSBR functions by HR. The role of this variant 
was tested by cloning the site-directed-mutated BRCA2 cDNA into a pRc/CMV 
vector: plasmids were transfected in NIH-GS cells (DR-GFP stable clones) and 
subsequently transfected with plasmids codifying for I-SceI enzyme. Mutation 
effects were tested through DSBR assays and the extent of repair by HR was 
measured by counting GFP-positive cells by FACS: the novel variant resulted 
unable to bind DNA, probably hampering the normal DSBR pathway. Moreover, 
26 variants with unknown clinical significance (VUSs) were also detected. 
Subsequent analysis of the mutation-carrier families resulted in the identification 
of at-risk subjects, including healthy male carriers, who were enrolled in 
surveillance healthcare programs. These results support the inclusion of an NGS-
based approach for BRCA1/BRCA2 mutation detection in a diagnostic workflow 
and further suggest the use of direct in vitro assays to test for functional role of 
novel mutations found in these genes. 
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1. BACKGROUND 
 
  Breast cancer (BC) is the most common malignancy in females worldwide 
with highest age-adjusted incidence in developed countries (73%) (Narod 2012). 
World Health Organization (WHO) report shows that BC incidence increases 2% 
per year (Parkin 2005). It is reported that 1.38 million of new cases were 
diagnosed in 2008 (Fig. 1) (Ferlay 2010). In Italy, about 38,000 new cases of BC 
are diagnosed each year, whereas the corresponding figure for Europe is 430,000 
(Parkin 2005) (Fig. 2). BC, considered a multifactorial disorder, is caused by both 
non-genetic and genetic factors and, with ovarian cancer, is one of the most 
common causes of death due to a neoplastic disease affecting women (Fig. 3). It is 
estimated that 1 in 8 women will develop breast cancer in her lifetime in the 
developed countries (Bray 2004). 
 
 
 
Figure 1. Estimated age-standardized incidence rates per 100,000 (World): breast cancer 
(Ferlay 2010). BC is now the most common cancer both in developed and developing regions 
with 690,000 new cases estimated in each region (population ratio 1:4). Incidence rates vary from 
19.3 per 100,000 women in Eastern Africa to 89.9 per 100,000 women in Western Europe, and are 
high (greater than 80 per 100,000) in developed regions of the world (except Japan) and low (less 
than 40 per 100,000) in most of the developing regions. 
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Figure 2. Estimated age-standardized incidence rates per 100,000 (Europe): breast cancer 
(Ferlay 2010). 
 
 
Figure 3. Estimated age-standardized incidence and mortality rates: women (Ferlay 2010). 
The incidence and the mortality of breast cancer is higher than the other most common cancers in 
women. 
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The three most important risk factors for BC, in decreasing order of 
importance, are gender, aging, and family history (Jatoi 2008). In addition, there 
are a number of recognized risk factors for BC development including hormonal, 
reproductive, and menstrual history, lack of exercise, alcohol, radiation, benign 
breast disease, and obesity (Hilgart 2012). Anyway, individual risk of developing 
BC increases in people carrying a germline predisposing mutation.  
About 90% of BCs are considered sporadic, whereas the remaining account for an 
inherited disorder, defined as "Hereditary Breast and Ovarian Cancers" (HBOCs).  
HBOC is an autosomal dominant disease with incomplete penetrance. (Meindl 
2011). It is characterized by a young age of onset and the presence in the family 
of numerous cases of cancer, not only of BC but also ovarian and/or cancer 
affecting other organs (Metcalfe 2008). Furthermore, although rarely, even men 
can develop BC, as greatly reported in literature (Bray 2004, Meindl 2011). 
The two high-penetrance genes most commonly mutated in HBOCs are the tumor 
suppressor genes BRCA1 and BRCA2 (BReast CAncer, early onset 1 and 2). 
BRCA1/BRCA2 germline mutations dramatically escalate the risk of developing 
HBOCs: women leading heterozygous mutations in BRCA1 or BRCA2 gene have, 
respectively, up to an 80% and a 60% risk of developing breast cancer and about 
60% risk of developing ovarian cancer (Parkin 2005). Therefore, is important to 
recognize predisposing-mutation carriers in high risk families, especially before 
the onset of the disease.  
 
 
1.1. Genetic risk of developing BC and non-genetic risk modifiers 
 
The risk for developing BC before the age of 40 is similar throughout the 
world (Narod 2013). However, the clustering of BC in families has been 
recognized for many years, suggesting the presence of an inherited component. It 
has been estimated that about 5-10% of all BCs arise in individuals carrying a 
germline predisposing-mutation (Musolino 2007). Although approximately 10%-
30% of BCs are attributed to hereditary factors, only 5-10% of them have a strong 
herited component, and just a small fraction (4%-5%) is explained by mutations in 
high penetrant genes transmitted in an autosomal dominant manner (Narod 2006).  
Within this group, only around 25% of cancer patients carry a germ line mutation 
in the two BC high susceptibility genes: BRCA1 (Miki 1994) and BRCA2 
(Wooster 1994). Indeed, the majority of inherited BCs are attributed to the 
HBOC-syndrome. Despite that, mutations in other genes causing familial 
syndromes, characteryzed by highly increased BC incidence, are estimated to 
cause around 5% of familial breast cancer (FBC). The most investigated are TP53, 
PTEN, STK11/LKB1, CDH 1, ATM, and CHEK2 (Robson 2007, Melchor 2013) as 
reported below (Fig. 4).  
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Figure 4. Distribution of breast cancer patients (Melchor 2013). A: Familial breast cancer 
represents a minor percentage of all breast cancer patients. B: Proportion of familial breast cancer 
patients due to germ line mutations in high, moderate, and low penetrance cancer genes. BRCA1 
and BRCA2 explain the vast majority of familial breast cancer attributed to identified cancer-
related genes; however, more families carry no mutations in known susceptibility genes and thus, 
are suggested to be caused by the inheritance of one or many low penetrance cancer genes 
(BRCAX families). 
 
 
Germ-line mutations in BRCA1 or BRCA2 genes confer an average 
cumulative risk of 65 or 39 % for BC and 39 or 11 % for ovarian cancer by age 70 
years, respectively (Borresen 1992, Chen 1998, Pharoah 2001, Evans 2002, 
Antoniou 2003, Leggett 2003). Fanconi anemia (FA) pathway genes have also 
been reported in about 5 % of FBC as moderate penetrance genes, given their 
incomplete segregation in affected families; this is the case of BRIP1, PALB2, 
RAD51C and XRCC2 (Seal 2006, Rahman 2007, Meindl 2010, Shamseldin  
2012), which  present similar penetrance to other non-FA genes, such as ATM, 
CHEK2, NBS1, RAD50, RAD51D and RAD51B (Meijers-Heijboer 2002, 
Thompson 2005, Heikkinen 2006,  Loveday 2011,Orr  2012,). Lastly, the recent 
identification of 41 low susceptibility genes, together with up to 26 genes 
previously identified, may explain around 14% of familial cancer risk 
(Michailidou 2013). However, there are still about 51% of FBC patients that show 
no mutation in any of these genes, and are classified into the category of non-
BRCA1/2 or BRCAX families. These families may either carry a mutation in a 
moderate-penetrance BC gene still to be identified or be explained by a truly 
polygenic model. In the latter, BC susceptibility would be conferred by the joint 
action of several low-penetrance loci (Easton 2007, Cox 2007, Stacey 2008, Rosa-
Rosa 2009, Gracia-Aznarez 2013). Attempts to identify a third breast cancer 
susceptibility locus (BRCA3) have so far been unsuccessful. This is probably 
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because no single gene can account for the remainder of families with a high 
incidence of breast cancer not associated with BRCA1 or BRCA2 mutations. 
 
 
Large epidemiological studies have been performed to identify potential 
modifiers of BC risk in predisposing-mutation carriers (Narod 2002). 
Briefly, risk is commonly measured in terms of the lifetime probability of 
developing breast or ovarian cancer (penetrance), but may also be measured in 
terms of the probability of developing cancer in a given year. Penetrance is 
usually defined in terms of a given age (e.g. up to age 70 years) and can be 
estimated in several ways. Ideally, a cohort of healthy subjects, no carrying 
mutations in the susceptibility gene of interest, is followed for a defined period of 
time and incident (new) cases of cancer are recorded. The cancer rate is then 
calculated from the number of new cases and the person-years of observation. 
Other methods are based on the reporting of cancers by family members. As 
reported before, the lifetime risk of BC in women who carry a deleterious  BRCA1 
or BRCA2 mutation is estimated to be as high as 80% - or roughly 10 times 
greater than that of the general population - but several estimates are lower (Table 
1) (Risch 2001, Antoniou 2003, Roy 2011). 
 
 
Table 1. Human cancers arising in BRCA1 or BRCA2 mutation carriers (Roy 2011).  
Cancer Type 
BRCA1 
mutations 
BRCA2 
mutations 
Features 
Breast 
70-80% lifetime 
risk 
50-60% lifetime 
risk Breast and ovarian cancer is the dominant cancer 
predisposition in BRCA1 and BRCA2 mutation carriers. 
BRCA1 mutation carriers develop breast and ovarian 
cancer at a younger age than BRCA2 mutation carriers. 
Ovarian 50% lifetime risk 30% lifetime risk 
Prostate 
Ashkenazi Jewish 
founder mutations 
are associated 
with increased 
risk 
20-fold increased 
risk 
<1% of BRCA2 mutation carriers have prostate cancer. 
Prostate cancer is even rarer in BRCA1 mutation 
carriers, except in the Ashkenazi Jewish carrier of 
BRCA1 mutations. 
Pancreatic 
Anecdotal 
evidence and case 
reports only 
10- fold increased 
risk 
<1% of BRCA2 mutation carriers have pancreatic 
cancer. No incidence has been clearly documented in 
BRCA1 mutation carriers. 
Gastric None reported Limited reports 
It is unclear whether stomach cancer is associated with 
BRCA2 mutations. 
Fallopian Tube Observed, but rare Rare 
This is a rare cancer overall and is still uncommon in 
BRCA mutation carriers. 
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Others None reported 
Brain, 
medulloblastoma, 
pharyngeal, CLL 
and AML 
Fanconi anaemia subtype D1 (caused by BRCA2 
mutations) is associated with cancer of the central 
nervous system. 
AML, acute myeloid leukaemia; CLL, chronic lymphocytic leukaemia 
 
 
A specific penetrance estimate represents a population average. However,  
penetrance may vary among populations, within populations and among 
individuals depending on several potential sources of variation. Allelic variation is 
due to different mutations in a single gene - for example, the position of the BRCA 
mutation within the coding region of the gene may influence the risk of breast or 
ovarian cancer. Among BRCA2 carriers, the risk of ovarian cancer is greatest for 
women carrying mutations within the ovarian cancer cluster region (defined by 
nucleotides 4075–6503). The risk of ovarian cancer is increased by 1.9 times for 
mutations within this region and the risk of BC appears to be decreased 
(Thompson and Easton 2001). Among BRCA1 mutation carriers, the relative 
proportion of ovarian cancer compared with  BC seems to be greater for mutations 
within the two-thirds of the gene (Gayther 1995). So, allelic variation can explain 
differences in penetrance among families and among countries.  
Another potential source of variation is represented by modifier genes. The 
penetrance of a major gene might be influenced by the presence of one or more 
variant in one or more minor genes acting as a genetic modifier. Several candidate 
HBOC modifier genes have been studied; most of them are related to the 
metabolism of sex hormones and DNA repair. Several published data supported 
the role of these genes (including androgen receptor, AIB1, HRAS and 
progesterone receptor) as potential risk modifiers in BRCA1 or BRCA2 mutation 
carriers (Phelan 1996, Rebbeck 2001).  
Environmental and lifestyle factors might also modify the risk of breast 
and ovarian cancer among BRCA mutations carriers. The risk varies from 
individual to individual, and it is increased in recent generations, underling the 
weight of environmental factors. To estimate the risk is important to consider also 
the age of menarche. It is not clear if this implies that neoplastic events take place 
in women as early as age of 10 years, or if the age of menarche is an indicator of 
later hormonal events, such as the regularity of established menses or circulating 
hormone levels. Early menarche is, however, associated with an increased risk of 
BC in BRCA1 carriers (Kotsopoulos 2005). Further, spontaneous and therapeutic 
abortion are considered risk modifiers; indeed, an interruption in pregnancy might 
be expected to be carcinogenic because the early changes of pregnancy result in 
increased mitoses, but are not accompanied by the later differentiation of the 
epithelial cells. On the other hand, is controversial the role of pregnancy on the 
risk.  In the general population, pregnancy offers protection against BC after the 
age of 40 years, but appears to increase the risk for very early-onset BC. This is 
consistent with the hypothesis that the ovarian hormones produced during 
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pregnancy are mitogenic and accelerate the growth of existing tumors. During 
pregnancy, breast differentiation occurs and thereafter the population of 
susceptible cells is reduced (Russo 1992). This might explain why pregnancy 
prevents BCs at a later age. However, the effect of pregnancy on hereditary breast 
cancer risk appears to differ for BRCA1 and BRCA2 carriers. In a large matched 
case-control study, Cullinane et al. (2005) reported that the risk of breast cancer 
did not decrease with pregnancy in BRCA1 carriers until four births were reached, 
after which there was only a modest protective effect. Furthermore, an early first 
birth does not appear to be protective for BC risk among BRCA1 carriers 
(Kotsopoulos 2006). This is consistent with the theory of Russo et al. (2001) that, 
in the absence of intact BRCA1, pregnancy fails to induce the expected degree of 
lobular differentiation.  
Moreover, a case-control study of breast-feeding and BC in BRCA 
mutation carriers reported a significant protective effect in women with BRCA1 
mutations, but not with BRCA2 mutations (Jernstrom 2004). In addition, several 
studies have shown that the incidence of BC declines in women with BRCA1 or 
BRCA2 mutations following an oopohorectomy (Rebbeck 1999, Kauff 2002, 
Eisen 2005). It is also important to establish whether or not oral contraceptives are 
hazardous to the breast, because their use has been proposed as a preventive 
measure against ovarian cancer (Narod 1998). It appears to be a small increase in 
BC risk associated with pill use among BRCA1 mutation carriers (Narod 2002). In 
addition, also drugs represent a BC risk modifier; tamoxifen, an anti-estrogenic 
drug routinely used in the treatment of estrogen-receptor-positive BCs, has also 
been demonstrated to reduce the risk of primary invasive and pre-malignant BC in 
high-risk women in North America (Vogel 2002), and of contralateral BC in 
unselected women (Early Breast Cancer Trialists’ Collaborative Group, 1998). 
The large National Surgical Adjuvant Breast and Bowel Project (NSABP) 
reported a highly significant reduction in the incidence of invasive BC among 
women randomized to tamoxifen, versus placebo (Vogel 2002). These data 
suggest that tamoxifen may be effective in the primary prevention of BRCA2 
mutation-associated BC, but not of BRCA1 ones. Moreover, there are little data 
available so far supporting the hypothesis that hormone replacement therapy 
(HRT) increases the risk of BC in women at high genetic risk. In the only study 
published to date by Rebbeck et al. (2005) is reported that the protective effect 
offered by oophorectomy was not attenuated by HRT. Furthermore, the potential 
use of antioxidants as chemoprevention in BRCA carriers has been discussed 
elsewhere (Kotsopoulos and Narod, 2005). One of the most investigated retinoid 
derivative is the Fenretinide. The capacity of this drug to accumulating  
preferentially in fatty tissue such as the breast, may contribute to the effectiveness 
against breast cancer (Sabichi, 2003). Moreover, phase III clinical trial data has 
suggested that fenretinide reduces breast cancer relapse in pre-menopausal women 
(Veronesi 2006). 
Summarizing all the above mentioned factors, the proposed BC risk 
modifiers in BRCA1 carriers relate to estrogen exposure and deprivation: the BC 
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risk declines after menopause; the cancers are largely limited to the breast and 
ovary, and BC is preventable by tamoxifen and by oophorectomy. The evidence 
for the importance of hormones in BRCA2-related carcinogenesis is much less 
compelling. The range of cancers seen among BRCA2 mutation carriers is wide 
and includes types that are classically associated with exogenous carcinogens, 
including melanoma and pancreatic cancer (The Breast Cancer Linkage 
Consortium, 1999). These observations imply that also non-genetic factors may 
modify the inherited risk. Knowledge of these risk factors is a very useful tool for 
managing risk and for developing prevention strategies. To address these points, 
over the last decade, researchers have developed a number of statistical models 
for predicting risk of harboring mutations in these genes and of subsequently 
developing breast and ovarian cancer (Vargas 2010). 
 
1.2. Breast cancer genetics 
 
Cancer is considered to originate from the contribution of both inherited 
and acquired genomic alterations, the first being dispensable, although strongly 
favorable for cancer induction. These genomic alterations are ultimately the result 
of the balance between the cell’s ability to maintain the integrity of genetic 
information and the effects of the environmental efforts to alter it. Acquired DNA 
changes, in addition to inherited predisposition, can push the cell outside the 
frame which regulates its life, and determinate the timing and shaping of its 
growth, division, metabolism and death. In particular, genetic alterations such us 
mutations, deletions and rearrangements can greatly affect the tumor suppressive 
activity of many genes, while insertions, duplications, translocations and gene 
fusions can push tumor promoting genes toward gains of function. 
Breast cancer susceptibility gene 1 (BRCA1) and breast cancer susceptibility gene 
2 (BRCA2) are the two major genes associated with HBOCs (Hamilton 2009).  
The BRCA genes, discovered approximately 15 years ago, represent a great 
opportunity to identify high-risk individuals for HBOCs (Pal 2012). As discussed 
above, germline inherited mutations can increase the risk for BC. BRCA1 and 
BRCA2 mutations account for approximately 5% of all BCs and 10-15% of all 
ovarian cancers. Specifically, high-penetrance mutations (eg, BRCA1, BRCA2, 
P53, PTEN, STK11/ LKB1, CDH1) are associated with a high lifetime risk of BC 
(40%–85%), whereas the low-to-moderate penetrance mutations (eg, in ATM, 
CHEK 2) are associated with a lower risk. These mutations linked to a  spectrum 
of syndromes that includes the HBOC-syndrome (BRCA1 and BRCA2), Li-
Fraumeni syndrome (P53), Cowden’s disease (PTEN), Peutz-Jeghers syndrome 
(STK11/LKB1), hereditary diffuse gastric carcinoma syndrome (CDH 1), ataxia-
telangiectasia (ATM), and a Li-Fraumeni syndrome (CHEK 2) (Jatoi 2008). 
Because of these evidences is important to identify women who carry 
predisposing mutations in order to use the latest medical advances in prevention, 
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early detection, and treatment. In particular, the most important genes which were 
proposed as highly penetrant for BC genetic susceptibility include BRCA1 and 
BRCA2, but also P53, PTEN, STK11/LKB1, and CDH1 genes, while some others 
like ATM, CHECK2, BRIP1, and PALB2 are considered as moderate genetic 
factors. P53 is involved in Li-Fraumeni syndrome and has about 1400 mutations 
which almost involve the transactivation domain. BC risk is increased of 4% in 
women who are carrier of PTEN mutations (Melchor 2013). It was described that 
PTEN loss of function not only is involved in tumor formation, but also causes 
resistance to targeted therapy. CDH1 gene encodes for E-cadherin which is 
determined as a primary indicator in addition to estrogen receptor   (ER ) for 
luminal epithelial tumors of breast (Chen 2000).Women who are carriers of 
CDH1 mutations have 39%-52% to be affected with BC in their life. On the other 
hand, CDH1 underexpression is associated with more metastasis and poor 
prognosis in either ER positive or negative BCs (Schrader 2011). Ataxia 
telangiectasia-mutated (ATM) gene encodes for ATM protein which is involved in 
double-stranded breaks DNA repair and regulation of cell cycle. It was shown that 
being carrier of heterozygote mutations of this gene is associated with increased 
risk of BC. However, the greater risk belongs to BRCA1 and BRCA2 genes which 
enhance the risk of BC progression up to 59%-87% and 38%-80% respectively. 
 
 
  BRCA1 and BRCA2 are tumor-suppressor genes, involved in a common 
pathway of genome protection (Narod 1994, 2004). These genes play a relevant 
role at different stages in the DNA damage response and DNA repair, since they 
code for proteins intimately involved in cellular growth and differentiation 
(Wooster 1994, Hall 1990, Jatoi 2008). The BRCA1 and BRCA2 gene mutations 
are transmitted in an autosomal dominant manner and therefore may originate 
from either the maternal or paternal side (Miky 1994, Iau 2001); then, the loss of 
the second allele (loss of heterozygosity (LOH)) can arise in mutation carriers. 
The effect of a defective BRCA1 or BRCA2 allele in the germ line must cause 
haploinsufficiency of HR to trigger the subsequent genetic alterations that result 
in cancer. Each offspring of a BRCA1 or BRCA2 mutation carrier has a 50% 
chance of inheriting that mutation, and a carefully documented family history is 
essential for the initial assessment of any woman concerned about a hereditary 
predisposition to BC. Hereditary BC predisposition should be suspected if a 
woman has:  i) multiple close relatives with breast and ovarian cancer diagnosed 
at an early age (before age 50 years); ii) bilateral breast cancer; iii) male BC in her 
family; and/or iv) an Ashkenazi Jewish ancestry  (Jatoi 2008). Indeed, alterations 
in the BRCA1 or BRCA2 genes are more common in certain ethnic and geographic 
populations (eg, Ashkenazi Jewish, Norwegian, Dutch, Icelandic), and specific 
mutations (founder mutations) often are clustered in particular ethnic groups 
(Ferla 2007). Clearly, women who carry BRCA mutations have a markedly 
increased risk of developing breast and ovarian cancer at an early age. Men who 
have BRCA1 or BRCA2 mutations (particularly BRCA2) also are at increased risk 
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for BC, although that risk is considerably lower than in women. Recently, it was 
estimated that the cumulative BC risk, by age 70 years, is about 1.2% for male 
carrying a BRCA1 mutation and about 6.8% for male carrying a BRCA2 mutation 
(Tai 2007). Specifically, BRCA2 mutations confer a lifetime risk of prostate, 
breast, and pancreatic cancers of about 20%, 6%, and 3%, respectively (Garber 
2005).  
  
1.3. BRCA1 and BRCA2  
The BRCA1gene, located on chromosome 17q, has a key role in DNA 
repair, cell-cycle regulation, transcriptional regulation, chromatin remodeling and 
control of multiple cell cycle checkpoints. This gene has 24 exons, spans 
approximately 100kb of genomic DNA, and encodes a 1,863 amino acid nuclear 
phosphoprotein, which acts as a tumour suppressor gene maintaining genomic 
stability (Rahman 1998). BRCA1 is a versatile protein that links DNA damage 
sensing and a several effectors of cellular network of signalling events (the DDR) 
that are triggered in response to genotoxic stress. BRCA1 interacts with tumour 
suppressors, DNA repair proteins and cell cycle regulators through its various 
functional domains and thereby has diverse roles in multiple DNA repair 
pathways (particularly HR, NHEJ and single-strand annealing (SSA)) and in 
checkpoint regulation (Fig. 5) (Deng 2000, Huen 2010). 
   
 
 
Figure 5. BRCA1 functional domains (Roy et al. 2011). 
 
The BRCA1 amino terminus contains a RING domain which binds BARD1 
(BRCA1-associated RING domain protein 1), and a nuclear localization sequence 
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(NLS). The central region of BRCA1 contains a CHK2 phosphorylation site on 
S988, necessary to the protein activation during the damage response. The 
carboxyl terminus of BRCA1 contains: a coiled-coil domain which binds PALB2 
(partner and localizer of BRCA2); a SQ/TQ cluster domain (SCD) that contains 
approximately ten potential ataxia-telangiectasia mutated (ATM) phosphorylation 
sites and spans amino acid residues 1280-1524; and a BRCT domain that 
facilitates the binding of phospho-protein such as ATM-phosphorylated abraxas, 
CtBP-interacting protein (CtIP) and BRCA1-interacting protein C‑terminal 
helicase 1 (BRIP1). The BRCA1-Abraxas-RAP80 macro-complex is associated 
with BRCA1 recruitment to sites of DNA damage (Wang  2007, Kim  2007, Liu 
2007, Sobhian 2007) through the association with ubiquitylated histones at DNA 
DSBs and appears to be involved in the G2/M checkpoint in response to ionizing 
radiation induced DNA damage (Wang 2007). The BRCA1-BRIP1 complex, 
which also contains DNA topoisomerase 2-binding protein 1 (TOPBP1), is 
associated with DNA repair during replication (Cantor 2001) and is necessary for 
the S‑phase checkpoint in response to stalled or collapsed replication forks 
(Greenberg 2006). The BRCA1-CtIP complex promotes CtIP-mediated 5′-end 
resection of DSBs (Yun 2009). In addition, the BRCA1-CtIP complex promotes 
ataxia-telangiectasia and Rad3-related (ATR) activation and homologous 
recombination (HR) by associating with the MRN complex (which is comprised 
of MRE11, RAD50 and NBS1) and facilitating DNA double-strand break 
resection (Yu 1998). The central region of BRCA1, which contains the SCD, is 
phosphorylated by ATM. This phosphorylation is important for BRCA1-mediated 
G2/M and S-phase checkpoint activation, as demonstrated by the expression of a 
BRCA1 mutant that lacks three of the phosphorylation sites (S1387, S1423 and 
S1524) and fails to rescue defective checkpoint activation and ionizing radiation 
hypersensitivity in a BRCA1-deficient cell line (Cortez 1999, Xu 2002). 
Moreover, BRCA1 contains an amino-terminal RING domain that has E3 
ubiquitin ligase activity (which catalyses protein ubiquitylation). Many inherited 
cancer-associated BRCA1 mutations have been found within the RING and BRCT 
domains, indicating that both domains are involved in suppressing breast and 
ovarian cancer (Friedman 1994, Shattuck-Eidens 1995, Couch 1996). BRCA1 E3 
ubiquitin ligase activity is enhanced when associated with the RING domain of its 
partner protein, BRCA1-associated RING domain protein 1 (BARD1) (Wu 1996). 
The BRCA1-BARD1 heterodimer generates polyubiquitin chains at 
unconventional K6 linkages that do not appear to signal for protein degradation, 
but may instead mediate downstream signaling events through mechanisms that 
are still unclear. BRCA1 ubiquitylation of CtBP-interacting protein (CtIP; also 
known as RBBP), may have a role in DSB repair pathway choice, as CtIP-
dependent resection promotes HR and inhibits NHEJ. The BRCA1-BARD1 
complex is involved in the activation of G1/S, S-phase and G2/M checkpoints. 
The G1/S-checkpoint requires phosphorylation of BRCA1 by ATM or ATR, 
which facilitates phosphorylation of p53 on S15, that is necessary for 
transcriptional induction of the cyclin dependent kinase (CDK) inhibitor p21 and 
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ionizing radiation induced G1/S checkpoint activation  (Siciliano 1997). The 
BRCT phosphopeptide-binding motif, which is conserved in multiple DDR 
proteins, is responsible for the association of BRCA1 with proteins 
phosphorylated on serine in SXXF motifs by ATM. The BRCA1-interacting 
proteins include abraxas, BRIP1 and CtIP. The binding of these proteins make up 
separate BRCA1 macro-protein complexes that have distinct and overlapping 
functions in the DDR. A fourth BRCA1-containing complex mediated through the 
BRCA1 coiled-coil domain is composed of PALB2 and BRCA2 and is 
specifically involved in DSB repair by HR (Sy 2009, Zhang 2009 BRCA1 is also 
required for RAD51 recruitment to the sites of DNA damage through its 
interactions with PALB2 and BRCA2. This interaction appears to be dependent 
on CHK2‑mediated phosphorylation of S988 on BRCA1. This protein combines 
with other tumor suppressors, DNA damage sensors, and signal transducers to 
form a large multisubunit protein complex, known as the BRCA1-associated 
genome surveillance complex (BASC) (Wu 1996). However, BRCA1 is directly 
involved in HR-mediated repair of DSBs (Wang 2007, Kim 2007) (Fig. 6).  
So, BRCA1 is a gatekeeper of genomic integrity and is implicated at multiple 
cellular levels including DNA repair by homologous recombination (HR) 
mechanism, checkpoint control, spindle cell regulation, and transcriptional 
regulation (Roy 2011). 
 
 
Figure 6. Molecular mechanisms of the DNA damage response (Roy 2011). In response to 
DNA doublestrand breaks (DSBs) or replication fork collapse (not shown), sensors (light blue) 
detect the damage, and signalling mediators (blue)  recruit or activate effectors (dark blue) that 
repair the damage and activate cell cycle checkpoints. 
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BRCA2, located on chromosome 13q, is made up of 27 exons, spans 
around 70kb and encodes a protein of 3418 amino acids (Fig. 7). BRCA2 is 
crucial as mediator of the HR mechanism by regulating the formation of the 
RAD51 filament; indeed, functions attributed to BRCA2 are mainly restricted to 
DNA recombination and DNA repair through a regulating role in RAD51 activity 
(Jensen 2013). These mechanisms assure the maintenance of genomic stability 
and more specifically, the correct operation of the homologous recombination 
(HR) pathway which repairs double-strand DNA breaks.  
 
Figure 7. BRCA2 functional domains (Roy 2011). 
 
The N terminus of BRCA2 binds PALB2 at amino acids 21-39 (Roy 2011). 
BRCA2 contains eight BRC repeats between amino-acidic residues 1,009 and 
2,083 that bind RAD51. Then, BRCA2 protein contains a DNA-binding domain 
(DBD), that binds single-stranded DNA (ssDNA) and doublestranded DNA 
(dsDNA), and eight BRC repeats that bind RAD51. The DBD contains five 
components: a 190‑amino-acid α-helical domain, three oligonucleotide binding 
(OB) folds that are ssDNA-binding modules, and a tower domain (TD) that 
protrudes from OB2 and binds dsDNA (Yang 2002). The helical domain, OB1 
and OB2 also associate with deleted in split-hand/split-foot syndrome (DSS1), 
which has been linked to BRCA2 protein stabilization (Kojic 2003, Li 2006, 
Kristensen 2010). Point mutations within BRC repeats that compromise 
interactions with RAD51, are found in individuals with HBOC syndrome 
(Venkitaraman 2009). In addition to facilitating the recruitment of RAD51 to 
ssDNA, the BRC repeats accelerate replication protein A (RPA)-displacement 
from ssDNA by RAD51, block RAD51 nucleation at dsDNA and facilitate 
RAD51 filament formation on ssDNA by maintaining the active ATP-bound form 
of RAD51 on ssDNA (Carreira 2009). The C terminus of BRCA2 contains an 
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NLS and a cyclin-dependent kinase (CDK) phosphorylation site at S3291 that also 
binds RAD51. The binding of RAD51 by the C terminus of BRCA2 has been 
shown to be dependent on CDK activity (Esashi 2005, Ayoub 2009). 
 
  In humans, the tumors developed in patients with germline heterozygous 
mutations in BRCA1 or BRCA2 are defective in HR-mediated repair. BRCA2-
related tumours usually express estrogen and progesterone receptors and tend to 
have features similar to sporadic BC, unlike BRCA1-related cancers (Tessaro 
1997, Oei 2006, Hamilton 2007). In general, if a mutation occurs in such genes 
then the normal controls on cell growth are compromised (Hamilton 2009). 
Therefore, loss of BRCA1 or BRCA2 leads to a deficiency in the repair of DNA 
double-strand breaks by homologous recombination (HR), leading to potentially 
mutagenic repair of DNA lesions by alternative mechanisms such as non-
homologous end-joining (NHEJ) and single strand annealing (SSA). Ultimately, 
genomic instability is developed and contributes to the cancer predisposition 
generated by loss-of-function mutations in BRCA1 or BRCA2 (Venkitaraman 
2002). Inactivation of the BRCA genes causes ostructural aberrations in 
chromosomes and aneuploidy, another common feature in cancer cells from 
BRCA-mutation carriers.These observations raise the question of whether BRCA1 
or BRCA2 have functions whose inactivation could interfere with chromosome 
segregation during mitosis, leading to the generation of daughter cells with 
abnormal numbers of chromosomes (Venkitaraman 2002). Anyway, both 
proteins, that work in concert in a common pathway to protect the genome during 
DNA replication, are essentials for the vital DNA repair process that uses the 
undamaged sister chromatid to carry out high-fidelity repair of predominantly 
replication-associated DNA double strand breaks (DSBs). HR appears to be the 
major mechanism for protecting the integrity of the genome in proliferating cells, 
because other DSB repair pathways are error-prone and generate chromosome 
deletions and translocations (Schlacher 2011).  
Most of BRCA1/BRCA2 predisposing mutations are frameshifts, and there 
are a number of missense variations with unclear pathogenicity (variants of 
unclassified significance-VUS), discussed below. 
 
1.4.  BRCA1 and BRCA2 mutations 
  Up to now, more than 3,000 distinct BRCA1 and BRCA2 sequence variants 
have been identified, including deletions, insertions, and many single nucleotide 
substitutions in coding or non-coding regions. The most common mutations are 
frameshift mutations due to small insertions/deletions, nonsense mutations, and 
disruption of splice site leading to entire nonfunctional BRCA proteins (Narod 
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2010). The higher rate of duplications/deletions in BRCA1 gene versus BRCA2 
(42% and 20%, resp.) is due to accumulation of Alu sequences (Thompson  2004). 
Large genomic rearrangements (LGRs) comprise about 1/3 of all mutations 
occurring in BRCA1 gene and are typically the result of homologous 
recombination between BRCA1 and its pseudogene (Zhang 2010). In general, 
most of BRCA2 mutations occur in exons 10 and 11, while most of BRCA1 
mutations usually occur in exon 20. These usually include insertions or deletions 
which raise the missense alterations and premature stop codon ending in truncated 
and nonfunctional protein. Some of the BRCA1/BRCA2 mutations show 
population specific patterns and some of them have been found in various studies 
from different populations. All of the most important and frequent BRCA1 and 
BRCA2 mutations which have been discovered so far are collected in several 
databases, such as Breast Cancer Information Core (BIC) – National Human 
Genome Research Institute (http://research.nhgri.nih.gov/bic/).  
The effects of BRCA1 and BRCA2 mutations on histological and 
pathological features, BC stage, especially the involvement of lymph nodes, are 
determining factor of BCs prognosis and survival rate. In general, the carriers 
show higher tumor stage, grade and ER negative tumors, and more metastasis to 
neighbor vessels relative to those who harbor other gene mutations (Musolino 
2007). Fatemeh Karami and ParvinMehdipour (2013) have richly described the 
mutation spectrum of BRCA1/BRCA2 mutations around several countries and the 
the genotype-phenotype correlations that occur in mutation carriers.  
 
1.4.1. VUSs 
A major limitation of BRCA1 and BRCA2 genetic testing is the number of 
inconclusive results due to Variants of Unknown Significance (VUSs). About 30-
50% of the genetic variants in BRCA1 and BRCA2, respectively, fall under this 
category (Gomez 2009). VUSs are mainly missense and splice site mutations 
without a definite role in carcinogenesis, thus representing a real clinical 
challenge. The interpretation of such variations can be difficult for physicians and 
problematic for individuals. The approach towards the evaluation of a VUS 
variant can be multifactorial, involving the in silico analysis, where specific 
softwares are used to predict the phylogenetic conservation and the protein 
modification caused. Additionally, segregation analysis of the variant with the 
disease can help in clarify its pathogenicity, even if only functional studies can 
verify its effect on protein structure and functions.  
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1.5.  Genetic testing: the state of the art and Next Generation Sequencing  
The progress made in the discovery of disease causing genes accelerated 
greatly with the initiation of the worldwide Human Genome Project in 1990. The 
investigation of the genome composition combined with new diagnostic 
approaches based on Next-Generation-Sequencing (NGS) methods, allow a better 
management of genetic diseases. While the number of tests for specific diseases 
continues to grow, one of the earliest presymptomatic mutation tests was for the 
HBOCs. Genetic testing for BRCA1 and BRCA2 is facilitated by the presence of 
one or more founder mutations in a population (Narod 2005, Previati 2013). 
Several molecular methods have been devised with the aim to detect mutations. 
They can be classified into methods detecting new mutations or known 
mutations/polymorphisms in focused genes. Identification of such mutations in 
cases appropriately preselected, using pedigree and clinical data, is justified in 
clinical practice, even though such techniques are still complex, time-consuming 
and expensive (Matyjasic 2008). It is recommended that a subject (the proband) 
with breast and/or ovarian cancer be the first tested to determine if a mutation is 
present in either the BRCA1 or  BRCA2 gene. Therefore, the first person tested for 
BRCA mutations should be a family member most likely to test positive, generally 
an individual who has developed BC at a young age or an individual who has 
ovarian cancer. Genetic testing allows the identification of high-risk women; 
however not all women who have a family history of BC are appropriate 
candidates for genetic testing. Women must be informed about the potential risks 
and benefits of genetic testing, and those who are found to carry mutations in the 
BRCA1 or BRCA2 genes should be advised of all management options (Evans 
2013). 
If a mutation is identified in the proband, other members of the family should be 
tested for the same mutation in order to manage the risk for cancer development. 
In a family in which a BRCA1 or BRCA2 mutation has been identified, individuals 
who do not carry the mutation are not at increased risk for breast or ovarian 
cancer. At worst, their risk is similar to that of the overall population, but it might 
be even less, because risk estimates of the overall population include women who 
carry the BRCA1 and BRCA2 mutations. According to findings on BC 
management, to reduce cancer-related mortality, women who have BRCA1 or 
BRCA2 mutations may wish to consider screening, chemoprevention, or 
prophylactic surgery. Early detection of cancer is beneficial especially for 
individuals at high risk for developing cancer. If a BRCA mutation is not found in 
a family member who has breast or ovarian cancer, the test is not informative and 
does not provide useful information to other family members. In such instances, 
the cluster of BC cases within a family might be attributable to mutations into 
other genes or to environmental or lifestyle factors.  
BRCA1 and BRCA2 genes are the most commonly mutated genes, but additional 
genes associated with hereditary BC are emerging (Walsh 2010). New advances 
in genomic technologies have led to parallel testing of multiple genes. Customized 
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NGS panels are now providing the simultaneous analysis of BC predisposition 
genes, from high- to intermediate-penetrant genes. Nonetheless, some of these 
genes have also been associated with increased risk of other cancers, such as 
ovarian, pancreatic, and colorectal cancer. BRCA1 and BRCA2 negative patients 
with a personal or family history of hereditary cancer can be eligible for 
customized gene panels testing. 
The low-scale, targeted gene/mutation analysis that currently dominates the 
clinical genetics field will ultimately be replaced by large-scale sequencing of 
entire disease gene pathways and networks, especially for the complex disorders 
like cancers. In addition, the perceived clinical benefit of whole-genome 
sequencing will outweigh the cost of the procedure, allowing for these tests to be 
performed on a routine basis for diagnostic purposes, or perhaps in the form of a 
screening program that could be used to guide personalized medical treatments 
throughout the lifetime of the individual. 
Even for genes extensively studied, as BRCA1 and BRCA2, the most thoroughly 
sequenced genes in the human genome, previously unseen variants continue to be 
detected frequently. In the United States, genetic testing of BRCA1 and BRCA2 is 
carried out almost exclusively by a single commercial company, whose protocol is 
based on PCR amplification of individual exons and Sanger sequencing of the 
products (Frank 1998). At one reference laboratory alone (Myriad Genetics, Salt 
Lake City, UT), these two genes have been sequenced completely in over 150,000 
people. In the process, upwards of 10,000 deleterious mutations and missense 
variants of negligible or uncertain clinical significance have been identified and 
recorded in a database (B. Ward, personal communication).Yet every week, 1% to 
2% of patients currently being tested demonstrate missense variants not seen 
before (B. Ward, personal communication), and each of these must be carefully 
analyzed in the attempt to assess its likely clinical effect before reporting out the 
result. While there are a number of deductive and informatics methods for making 
these assessments (Aymé 2008), in many cases it is simply impossible to draw 
any conclusion without extensive clinical follow-up of those individuals carrying 
the variants. Myriad maintains extensive tracking and correlation data, and will 
sometimes revise the clinical classification of a missense variant years after its 
first detection. In 2007, a quantitative DNA measurement assay (BART) was 
added as a supplementary test to detect large exonic deletions and duplications 
that are not detectable by PCR amplification approaches (BRACAnalysis, 
http://www.myriadtests.com/provider/doc/BRACAnalysisTechnicalSpecification.
pdf). In Europe, genetic testing of BRCA1 and BRCA2 is more widely available 
(Matthijs 2008). Sequencing of the more moderate-risk BC genes is available in 
various research or commercial diagnostic laboratories (GeneClinics, 
http://www.ncbi.nlm.nih.gov/sites/GeneTests/?db=GeneTests), but is still not 
routinely performed.  
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1.6.   BRCA analysis 
Direct sequencing is considered the gold standard for direct identification 
of specific sequence alteration, but it is time consuming and costly. Because of 
that, is important to find a cost effective scanning technique to identify regions 
containing genetic variants, which can be subsequently subjected to DNA 
sequencing, and to develop a reliable alternate faster and less expensive method 
for routine BRCA1 and BRCA2 mutation screening program. Some of the 
techniques which are commonly used are single-strand conformation 
polymorphism (SSCP), restriction endonuclease fingerprinting (REF)- SSCP, 
conformation-sensitive gel electrophoresis (CSGE), fluorescence-based 
conformation-sensitive gel electrophoresis (F-CSGE), two dimensional gene 
scanning (TDGS), protein truncation test (PTT), and denaturing high performance 
liquid chromatography (DHPLC). Gerhardus et al. (2007), provide a systematic 
study of analyzing the accuracy of different scanning methods using for BRCA1 
and BRCA2 mutation screening. Similarly, K. Somasundaram (2010) used CSGE 
as a method of scanning to identify the potential exons where the mutations are 
likely to occur, followed by DNA sequencing to locate and find out the nature of 
mutations. The speed, accuracy, efficiency, and cost-effectiveness of DNA 
sequencing have been improving continuously since the initial derivation of the 
technique by Maxam and Gilbert (1977) and Sanger et al. (1997) until the next 
generation sequencing techniques (Bosch 2008). Next generation sequencing 
(NGS), massively parallel or deep sequencing are related terms that describe a 
DNA sequencing technology which has revolutionized genomic research. Using 
NGS an entire human genome can be sequenced quickly. In contrast, the previous 
Sanger sequencing technology required over a decade to deliver the final draft. 
The spectrum of DNA variations in a human genome comprises single base 
changes (substitutions), small insertions and deletions, but also large genomic 
deletions of exons or whole genes, and large rearrangements, such as inversions 
and translocations. Traditional Sanger sequencing is restricted to the discovery of 
substitutions and small insertions and deletions. For the remaining mutations 
dedicated assays are frequently performed, such as fluorescence in situ 
hybridisation (FISH) for conventional karyotyping, or comparative genomic 
hybridisation (CGH) microarrays to detect submicroscopic chromosomal copy 
number changes such as microdeletions. However, these data can also be derived 
from NGS sequencing data directly, obviating the need for dedicated assays while 
harvesting the full spectrum of genomic variation in a single experiment. Recent 
advances in sequencing technologies have dramatically increased the speed and 
efficiency of DNA testing (Walsh 2010). 
NGS technologies involve the isolation of DNA followed by the creation 
of single stranded DNA libraries. Libraries can be obtained using several different 
approaches. The key differentiating features specific to each commercial platform 
are in the subsequent steps. The DNA fragments are modified with the ligation of 
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an adapter and amplified using a unique adapter chemistry proprietary to each 
individual commercial platform. These modified DNA library molecules are then 
amplified either on a bead (emulsion based PCR method-454 and SOLiD) or a 
glass slide (bridge amplification-Illumina). The amplified single DNA strands on 
the bead or glass slide are then paired with complementary DNA nucleotides in 
individual flow cycles of ATGC templates. A complementary match unique to the 
DNA template strand results in the release of a signal detected by the sequencing 
instrumentation (Meldrum 2011).  
Massively parallel sequencing was demonstrated to be a good strategy for the 
identification of genes responsible for monogenic diseases or diseases with a high 
degree of genetic heterogeneity (Gracia-Aznarez 2012), and one of the largest 
field of the NGS application is cancer. Although capillary-based cancer 
sequencing has been ongoing for over a decade, these investigations were limited 
to relatively few samples and small numbers of candidate genes. With the advent 
of NGS, cancer genomes can be systemically studied in their entirety. This may 
provide many benefits including a more precise diagnosis and classification of the 
disease, more accurate prognosis and treatment choice, and potentially the 
identification of ‘drug-able’ causal mutations. In addition, individual cancer 
sequencing may, therefore, provide the basis of personalized cancer management 
(Behjati 2013). To identify as many mutations as possible that are responsible for 
inherited predisposition to breast and ovarian cancer, it is useful to analyze 
multiple genes, especially, at first, BRCA1 and BRCA2.  
The advent of next-generation technologies (such as the Roche 454 GS FLX+, 
llumina Hiseq 2000, Applied Biosystems SOLID and HeliScope single-molecule 
sequencer machines), which allow a human genome to be sequenced in a single 
week-long run, has led to a large shift in our understanding of the mutations that 
drive cancers (Weaver 2011). It is therefore necessary to screen numerous genetic 
loci to decide on the best course of clinical management for an individual patient 
and this must be done in a rapid and cost-effective manner. Desmedt et al. (2012) 
described several NGS technologies applied to BC research. Authors underlined 
the possibility of integrating NGS in clinical practice in order not only to better 
understand the BC biology, but especially to create a new molecular classification 
system for the disease, to refine BC prognosis and to identify predictive markers 
for response to commonly administrated anticancer treatments. Indeed, they 
pointed out as tumor-specific DNA rearrangements could be detected in the 
patient’s plasma, suggesting that NGS could be used to personalize the monitoring 
of the disease. In a recent article, Thompson and colleagues (2011) present a 
development of a NGS technology - the HeliScope sequencer - that enabled them 
to detect BRCA1 mutations, as a model of a clinical diagnostic protocol. 
Moreover, to evaluate the accuracy of DNA capture followed by massive parallel 
sequencing, Walsh (2010) and colleagues developed a genomic assay to capture, 
sequence, and detect all mutations in 21 genes, including BRCA1 and BRCA2, 
with inherited mutations that predispose to breast or ovarian cancer (Walsh 2010). 
Another NGS approach was performed through 454 GS Junior (Roche) 
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technology by Vaca-Paniagua (2012) and colleagues in Mexican women 
population . Furthermore, Pern (2012) and collaborators, performed a study using 
several genetic approach, including a NGS method, in order to investigate the 
genetic basis of the Triple-negative breast cancer (TNBC), an aggressive form of 
breast carcinoma with a poor prognosis. Microfluidic array PCR and NGS (GS 
FLX 454 (Roche)  pyrosequencing technology) was used for BRCA1 and BRCA2 
analysis, while conventional high-resolution melting (HRM) and Sanger 
sequencing was applied to study the coding regions of PALB2 and BRD7, 
respectively. Further, in order to identify new high susceptibility genes in familial 
BC, Gracia-Aznarez (2012), performed a NGS (through an Illumina Genome 
Analyzer II technology) approach to analyze 7 BRCA1/BRCA2 negative families, 
each having at least 6 affected women with early-onset BC (Gracia-Aznarez, 
2012). 
As shown, the recent use of NGS strategies has been revolutionary in the research 
of BC genetics, like largely demonstrated by the high number of publications 
about these methodologies (Natrajan 2012, Nik-Zainal 2012, Mavaddat 2013). 
The ability of NGS technology to deliver information on whole genome 
sequences of different cancers will be an invaluable tool to the future pathologist 
and clinician. The data obtained from NGS can provide a comprehensive 
assessment of the genomic landscape associated with the genesis and evolution of 
different cancers (Gullapalli 2012). Concerning these great analysis performed on 
genes causing HBOCs, large consortia such as the Cancer Genome Atlas (TCGA) 
and the International Cancer Genome Consortium, and such companies like 
Myriad described before, have been formed to sequence thousands of cancers and 
generate a freely available dataset of DNA sequence changes in different cancer 
subtypes. 
 
The present study was performed through the Genome Sequencer (GS) 
FLX System from 454-Roche, present at CEINGE in the High-Throughput 
Sequencing core-laboratory. The 454 system was the first next-generation 
sequencing platform available as a commercial product (Rothberg 2008). The first 
step for samples sequencing through this method is the creation of DNA libraries, 
by Multiplicom MASTR assays, creating a mixtures of short, adaptor-flanked 
fragments (Fig. 8). The subsequent clonal amplification of the obtained libraries is 
performed by emulsion PCR (emPCR). This procedure provides the capture of 
library fragments on the surface of microscopic beads (28-μm), under conditions 
that favor the linkage of one fragment per bead. The beads are isolated and 
compartmentalized into the droplets of a PCR-reaction-mixture-oil-emulsion, so 
that PCR amplification occurs within each droplet resulting in million of different 
beads, each carrying about ten million copies of a unique DNA template. 
Subsequently, the emulsions are broken, the DNA strands are denaturated and the 
beads carrying single-stranded DNA templates are enriched and deposited into the 
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wells of a fiber-optic slide (PTP). A sequencing primer is hybridized to the 
universal adaptor for next reactions (Fig. 9-11). 
Sequencing is performed by the pyrosequencing chemistry. At each of several 
hundred cycles, a single species of unlabeled nucleotide is introduced. On 
templates where this results in an incorporation event, pyrophosphate is released. 
Via ATP sulfurylase and luciferase, the incorporation events immediately drive 
the generation of a burst of light, which is detected by the CCD camera as 
corresponding to the PTP coordinates of specific wells. Across multiple cycles, 
the pattern of detected incorporation events reveals the sequence of templates 
represented by individual beads. The 454 FLX instrument generates ~400,000 
reads per instrument-run at lengths of about 450 bp (Fig. 12). 
 
 
 
 
 
 
Figure 8. Creation of DNA libraries through Multiplicom MASTR assays. In the 1
st
 PCRs 
each library was tagged with Tag sequences and A and B adaptors, that allowed the binding of the 
specific “multiple identifiers” (MID) in the 2nd PCR reactions. 
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Figure 9. Em-PCR. Single-strand DNA is annealed to Capture beads and emulsified in a water-
in-oil emulsion with PCR reagents, in order to allow a clonal amplification in each microreactor. 
 
 
 
 
Figure 10. Enrichment of the reaction beads. After the amplification reaction, the emulsions are 
broken and the beads with amplified DNA are purified using magnetic enrichment beads. 
 
 
 
Figure 11. DNA beads are loaded into the PTP  device. A: Micro wells of the PTP. B: Loading 
of DNA beads. C-D-E: DNA beads packed into wells with surrounding beads and sequencing 
enzymes.  
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Figure 12. High Throughput Sequencing Open view of the GS FLX System (Roche). 
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2. AIMS OF THE STUDY 
 
 
The first aim of the present project was to set-up and validate a NGS-based 
approach to characterize each BRCA1/BRCA2 mutation in DNA of patients 
affected by HBOCs. The validated procedure was subsequently used to perform a 
large population-based study to assess the presence of BRCA1/BRCA2 germline 
predisposing mutations in HBOC at risk subjects. Once a pathogenetic mutation 
has been identified in the affected women, it was investigated also in the healthy 
people composing their high-risk families, in order to identify mutation carriers 
before the disease onset. Indeed, one of the principal targets of this study was to 
underline the importance of breast cancer early prevention, especially in young 
women, and accordingly the improvement of clinical management, 
pharmacological treatments, surgery options, and of the patient’s care in order to 
direct the treatments ever more toward a personalized medicine.  
Since novel variants, predicted to be potentially pathogenetic, were 
identified, the second aim of the project was to verify their effects on disease 
onset and development, through in silico gene function predictions, functional 
studies and in vitro cellular assays. 
 
 
 
 
 
 
 
 
 
30 
 
 
3. MATERIALS AND METHODS 
 
3.1. Patient samples and ethics 
Samples and clinical data were obtained from a total of about 300 women 
attending the Senology Unit of the “Istituto Nazionale dei Tumori - Fondazione 
G. Pascale” of Naples. All participants were fully informed about the study and 
provided written informed consent prior to samples collection. The protocol was 
approved by the Ethics Committee of the School of Medicine Federico II, Naples, 
Italy, and carried out in accordance with the Declaration of Helsinki, good clinical 
practices, and local ethical and legal requirement.  
In particular, the women included in this study should have at least one of 
specific selection criteria, such as early disease onset (especially “under forty”), 
tumors positive family history, advanced tumor staging, etc., discussed below. All 
patients were clinically approached, for everyone were collected extensive family 
information: a three-generation genealogy of each family was made in order to 
value the possible family history of breast cancer and other malignancies. 
 
 
3.1.1. Patients selection criteria  
Patients enrolled for the BRCA1/2 screening must have at least one of the 
following specific selection criteria:  
 Young age (<40 years) of onset of BC;  
 Invasive and/or bilateral BC (any age) and/or multiple organ cancers;  
 Family history of breast or ovarian cancer; 
 Invasive ovarian cancer (any age); 
 One first degree female relative with BC at <40 years of age; 
 One first degree male relative with BC at any age; 
 One first degree relative with bilateral BC where the first primary was 
diagnosed at <50 years of age; 
 Two first degree relatives, or one first degree plus one second degree 
relative, with BC at any age; 
 One first degree or second degree relative with BC at any age plus one first 
degree or second degree relative with ovarian cancer at any age (one of 
these should be a first degree relative); 
 Three first degree or second degree relatives on the same side of the family 
with BC at any age; 
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 If more than one relative is involved, they should be on the same side of 
the family. 
 
3.2.   DNA Isolation 
Genomic DNA was isolated from peripheral blood of the patients using the 
Nucleon BACC3 Genomic DNA Extraction Kit (GE Healthcare, Life Sciences) 
according to the manufacturer’s instructions. Then, samples quantification was 
done through the NanoDrop 2000c Spectrophotometer (Thermo Scientific).   
 
 
3.3. 454-Pyrosequencing 
The creation of the  DNA library of amplicons covering all the coding 
regions of BRCA1 and BRCA2 genes was performed using the BRCA MASTR 
v2.1 Assay kit (Multiplicom), following  the manufacturer’s instructions (Fig. 8).  
In brief, for each patient a template of 50ng of gDNA were used to perform a five 
reactions multiplex PCR covering the exons and about 50bp of the flanking sites 
of the intronic genetic regions. After the amplification, a 1:1000 dilution of the 
purified multiplex PCR products were re-amplified using specific molecular 
identification (MID) adaptors (Multiplicom) for each patient. Amplicons from the 
second PCR were cleaned and purified using the Agencourt AMPure XP Beads 
(Beckman Coulter), according to the manufacturer’s recommendations. Then, 
amplicons, having a length ranging from 350 to 500 bp, were subjected of quality 
and quantity controls using the Experion DNA 1k Analysis kit (Bio-Rad). An 
equimolar concentration of the five PCR products were pooled together to create a 
BRCA amplicon library of each sample in order to generate the Sequencing 
Master library. The subsequent clonal amplification of the obtained libraries was 
performed by emulsion PCR (emPCR), using the GS FLX Titanium emPCR kit-
LibA MV (Roche), according to manufacturer’s instructions (Fig. 9-11). Next, a 
total of 60 patients were pooled together into 2 regions of the wells of a fiber-
optic slide (PTP) and were sequenced in each single sequencing run. 
Pyrosequencing of the Master libraries were performed using the 454 GS FLX 
Tianium Series (Roche) technology (Fig. 12).  
 
 
3.4.   Bioinformatics and sequencing results validation 
 
The downstream data analysis was carried out through the SeqNext tool 
(JSI Medical Systems) SeqPilot software version 3.5.2 (JSI Medical Systems, 
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www.jsi-medisys.de) using to the reference sequences BRCA1 (NG_005905.2; 
Isoform  NM_007294.3) and BRCA2 (NG_012772.1; Isoform NM_000059.3) 
given in the NCBI-database (http://www.ncbi.nlm.nih.gov) (Fig. 13). According 
to the JSI Medisys approach, was considered a minimum absolute coverage of 
40X per exon. Only the distinct mutations present in both sequencing directions, 
and with a minimum coverage of 10% default, excluding homopolymers, were 
considered in the genetic analysis. All sequence variants were named according to 
the nomenclature used by Human Genome Variation Society, HGVS 
(http://www.hgvs.org). The variants found were characterized using the Breast 
Cancer Information Core (BIC) Database, the Ensemble Database 
(http://www.ensembl.org) and the Human Genome Mutation Database, HGM 
(www.hgmd.cf.ac.uk). The BRCA1/BRCA2 identified variants were classified 
according to theirs in silico gene function predictions and biological significance.        
The results were validated by standard Sanger sequencing of the patient’s DNA. 
The BRCA exons PCR primers amplification were designed to prime the intron 
sequences flanking the corresponding exon; in this way, all coding sequence 
alterations could be detected. Sanger sequencing allowed to verify the presence of 
found variations in patient’s DNA and provides the basis for a simplified test for 
at-risk relatives. 
 
Figure 13. SeqNext tool (JSI Medical Systems) SeqPilot software: example analysis page. 
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3.5. Functional Assays 
Each novel variant identified was analyzed by in silico predictions, using 
many bioinformatic programs described below. Variants resulted “deleterious” or 
“probably pathogenetic” or that showed particular alterations into protein folding 
or translation, were subsequently tested through functional studies and/or in vitro 
cellular assays. 
 
3.5.1.   BRCA1 splice variant 
To test the splice variant effects several bioinformatic predictions were 
performed through Human Splice Finder (http://www.umd.be/HSF/) and 
NetGene2 (http://www.cbs.dtu.dk/services/NetGene2/).  Patient RNA was isolated 
from peripheral blood using TRIzol® protocol (Ambion, Life Technologies). 
Retrotranscription reactions of patient and controls RNAs were performed by 
High Capacity cDNA Reverse Transcription Kits (Applied Biosystems) according 
to the manufacturer’s instructions.  
CDNAs were amplified using different primers pairs designed ad hoc (primers list 
shows in table 2). To demonstrate the presence of the target BRCA1 cDNA and to 
avoid the amplification of gDNA contamination, a pair of primers was designed 
on flanking cDNA exons. Another pair was designed to cover about 400bp of the 
retained intron, and then was performed another PCR reaction using a forward 
primer complementary to a cDNA region and a reverse primer annealing to the 
retained intronic region. PCR reactions were performed using PfuUltra High-
Fidelity DNA Polymerase (Agilent Technologies), following a touch-down 
amplification protocol (Table 3). Results of PCR amplifications were analyzed 
through Sanger sequencing.  
  In addition, a restriction map was performed on the sequence of the 
retained intron and another one was performed on the portion of the cDNA 
sequence amplified by designed primers described, using NEBcutter V2.0 
(http://tools.neb.com/NEBcutter2/) and Sequence Manipulation Suite 
(http://www.bioinformatics.org/sms2/rest_map.html) bioinformatic tools. The 
NcoI (BioLabs) restriction enzyme was chosen for the enzymatic digestion of 
patient and controls amplified cDNAs, and of a gDNA used as control of enzyme 
functionality. The reaction was performed using 0,5 µl of NcoI enzyme for 1 µg 
of  DNA to digest, added to 5 µl of enzyme buffer, without BSA. Then, DNA 
fragments were analyzed by DNA Chip 1K (BioRad). 
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Table 2. Primers list to validate the splice variant on BRCA1 cDNA. 
 
 Primer sequence Product Length (bp) 
BRCA1_cDNA_fw CAACATGCCCACAGATCAAC 885 
BRCA1_cDNA_rw AATTTCCTCCCCAATGTTCC 885 
BRCA1_intr21_fw CCCACCCCTGTAATCACAAC 472 
BRCA1_intr21_rw GATCCCCAGGAAGGAAAGAG 472 
BRCA1_intr21_ctr_rw TCCCTCCCCCTCCTCTCTGT 1417 
 
 
Table 3. PfuUltra touch-down amplification protocol. 
 
Temperature Cycles 
95° x 5’ 1 
95° x 30’’ 
55° x 60’’   – 0,5°/cycle 
72° x 65’’ 
14 
95° x 5’ 1 
95° x 30’’ 
55° x 60’’ 
72° x 65’’ 
25 
72° x 5’ 1 
4° ∞ 
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3.5.2. BRCA2 missense variant 
  
  The impact of protein alteration was evaluated using SIFT 
(http://sift.jcvi.org/) and PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/) 
computational approaches. The bioinformatic evaluation of the variants was 
performed also using “Database of human missense variants mapped to 3D 
protein structures” (http://decrypthon.igbmc.fr/msv3d/cgi-bin/analyse).  
The last 2500bp of wt BRCA2-10921bp-cDNA, including the DNA binding sites, 
the nuclear localization sequences (NLS) and one of the RAD51 binding regions, 
were cloned into a pRc/CMV vector (Life Technologies). Cloning experiments 
were performed into the Apa I/Not I restriction enzymes sites, and fragments were 
ligated by T4 DNA Ligase (New England BioLabs). The constructs were cloned 
in frame under the vector CMV promoter and using an initial ATG with the 
complete translation started sequence, including the Kozak consensus sequence, 
to assure the translation of the mutant proteins. Clones were purified from 
Cloning Competent DH5a™ Cells (Life Technologies) through GenElute Plasmid 
Miniprep (Sigma-Aldrich) procedures. Two single-bases mutagenesis reactions on 
the wt construct were performed, through QuikChange Lightning Mutagenesis Kit 
(Agilent Technologies): into one clone was introduced the investigate variant and 
into another one was introduced a reported deleterious mutation used as positive 
control for the next assays. Mutants were amplified and purified from XL10-Gold 
Ultracompetent Cells (Agilent Technologies) using QIAGEN plasmids Maxi kit.  
To test the BRCA2 mutant proteins expression, the wt fragment and the mutants 
were transfected in NIH-3T3 cells, using Lipofectamine 2000 (Invitrogen). 
Whole-cell extracts and nuclear fractions were used for Western blot analysis. For 
the preparation of the cellular extracts, monolayer cultures were harvested in cold 
phosphate-buffered saline after 36 hours and sonicated in lysis buffer (50 mM 
Tris·HCl, pH 7.5, 150 mM NaCl, 0.5% Nonidet P-40, 10% glycerol, 0.4 mM 
EDTA, 50 mM NaF, 1 mM sodium vanadate, 1 mM phenylmethylsulfonyl 
fluoride) added to a protease inhibitor cocktail (2 mM PMSF, 5 ug/mL leupeptin, 
5 ug/mL pepstatin). Nuclear proteins were isolated from whole-cell lysates 
through 3 minutes of pulse Bioruptor (Diagenode) sonication. The extracts were 
clarified by centrifugation at 16,000 × g at 4 °C, and the protein concentration was 
determined by the Bio-Rad protein assay according to manufacturer's instructions. 
Proteins (50µg) were separated on 8% and 12% low bis acrylamide gels, 
subjected to SDS-PAGE, transferred onto a polyvinylidene difluoride Immobilon 
P membrane (Millipore), and blocked with 5% milk-TBST (50mMTris [pH 7.5], 
150mMNaCl, 0.05% Tween 20) for 1 h at room temperature. Immunodetection of 
the BRCA2 mutant proteins was performed using the C-terminal BRCA2 ( (T-18) 
sc-21230; Santa Cruz Biotechnology, 1:1000) goat primary antibody. Actin, used 
to normalize the amount of protein in different samples, was revealed using anti-
β-actin (Sigma-Aldrich, 1:1000) mouse primary antibody. Goat polyclonal anti-
goat and anti-mouse IgG conjugated to horseradish peroxidase were used for 
secondary antibodies (GE Healthcare). Bands were detected using ECL 
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chemiluminescence detection methods (PerkinElmer) and exposure to X-ray film 
(Molecular Technologies).  
Transient transfections of plasmids were done with the DNAs described 
before, by using Lipofectamine 2000 (Invitrogen), following the instructions of 
the manufacturer, into NIH-GS cells, stable containing the pDR-GFP plasmid, and 
subsequently trasfected with I-SceI-ER plasmids, described in reference (Gunn 
2012 and Stante 2009). PDR-GFP and I-SceI-ER plasmids were kindly provided 
by prof. Giuseppina Minopoli. To obtain the NIH-GS clones, NIH-3T3 cells were, 
at first, transfected with pDR-GFP plasmid (Stante 2009). 48 hours after 
transfection, cells were selected with puromycin (3 μg/ml) (Sigma-Aldrich) for 5 
days. Puromycin-resistant colonies were pooled and amplified under puromycin 
selection to obtain NIH3T3-G stable clones. Resistant colonies were pooled and 
amplified (Stante 2009). 
NIH-3T3 fibroblasts were grown in Dulbecco's Modified Eagle Medium 
(DMEM, Sigma-Aldrich) supplemented with 10% Fetal Bovine Serum (Sigma-
Aldrich), 2mML-Ultraglutamine 1 (Lonza), and 1% penicillin and streptomycin 
(100µg/ml streptomycin, and 100 units/ml penicillin) (Sigma-Aldrich). 
After the transfection of I-SceI-ER into NIH3T3-G stable clones, cells became 
NIH-GS. 24 hours from transfection NIH-GS cells were exposed to 1 μM 4-OH-
tamoxifen (Calbiochem) to allow cells growth upon I-SceI-ER induction. 48 hours 
after I-Sce-I-ER induction, cells were harvested, resuspended in PBS at 500,000 
cells/ml and GFP positive cells were counted with FACScanto (BD Biosciences, 
San Jose, CA) instrument. Each experiment was performed at least in triplicate by 
counting 30,000 events per sample. 
The extent of repair, into NIH-GS cells, was measured by counting GFP positive 
cells by FACS, the Annexin V Apoptosis detection was performed using the  
Annexin V-APC Staining Protocol (BD Biosciences) according to manufacturer's 
instructions; GFP emission in transfected cells was also observed through 
fluorescence microscopy (Leica DMS 4000B).  
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4. RESULTS AND DISCUSSION 
 
Over 2,000 different mutations have been reported in BRCA1/BRCA2 
genes including deletions, insertions, and many single nucleotide substitutions in 
coding or noncoding sequences. The most common mutations are attributed to 
frameshift due to small insertions/deletions, nonsense protein-truncation, and 
disruption of splice site leading to entire nonfunctional BRCA proteins. 
According to geographic areas, there are several predominant founder mutations 
in the same populations, different from the others, as greatly reported by Fatemeh 
Karami and Parvin Mehdipour (2013).  
About 12.5% of the analyzed patients, including several men, carried a 
mutation in the BRCA1/BRCA2 genes mostly known to be causative (Table 4). 
Mutations were found in patients affected by HBOC principally, but also in 
healthy carrier with strong familial history of cancer. The analyzed population, 
derived mainly from Southern Italy, showed the presence of predominant 
mutations that occurred many times with an allelic frequency ranging from 
0.16%, for mutations detected once, to 0.5% for more frequent mutations such as 
c.6037A>T p.K2013X in BRCA2 gene (occurred twice) and c.5263_5264insC  
p.Q1756fs*74  in BRCA1, discussed below. Therefore, the most frequent BRCA1 
gene mutation is c.5263_5264insC (c.5266dupC or 5382insC) which was also 
found roughly in all of the populations. The maximum likelihood method 
considering any mutation or crossing-over occurrence has shown that this 
insertion at first came from Scandinavia, probably Denmark as it includes the 
founder mutation in Danish population around 200 AC. However, Russia is 
second candidate for occupying the primary origin of it, and after that it was 
disseminated to other areas including Ashkenazi Jews. It was also proposed that 
5382insC has entered into the Ashkenazi Jewish through affecting Polish 
population about 400 yrs earlier. 5382insC is the most important and prevalent 
BRCA1 mutation in European countries while Asian and American BC individuals 
rarely demonstrate it (Hamel 2011). In our population was found in 3 patients and 
confirmed in many relatives of their high-risk families. One representative 
genealogy of an analyzed patient shows the presence of the variant in the family 
(Fig. 14).  
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Table 4. Causative BRCA1 and BRCA2 mutations found into analyzed population. 
Gene Exon HGVS
1
 cDNA 
BIC 
Designation 
HGVS
1
 Protein 
Mutation 
Type 
Clinically 
Important 
(BIC) 
Ref. number 
NCBI 
Allelic frequency 
on 600 alleles  
BRCA1 5 c.181T>G  C61G p.Cys61Gly Missense Deleterious rs28897672 0.16% 
 
11 c.2761C>T  Q921X p.Gln921Ter Nonsense Deleterious rs80357377 0.3% 
11 c.3351_3352insT 
3470insT 
(Q1118SfsX*4) 
p.Val1117_Gln1118?fs Frameshift Deleterious rs80357785 0.16% 
11 c.3403C>T Q1135X p.Gln1135Ter Nonsense Deleterious rs80357136 0.16% 
11 c.3419G>T S1164I p.Ser1164Ile Nonsense Deleterious n.r.
2
 0.16% 
14 c.4484G>T R1495M p.Arg1495Met Missense Deleterious rs80357389 0.16% 
16 
c.4964_4982del 5083del19 
(S1655Yfs*16) 
p.Ser1655_Glu1661?fs 
Frameshift Deleterious rs80359876 0.16% 
18 c.5123C>A  A1708E p.Ala1708Glu Missense Deleterious rs28897696 0.16% 
18 c.5153-1G>C IVS18-1G>C - 
Intervening 
Sequence 
Deleterious rs80358137 0.16% 
19 c.5153G>A W1718X p.Trp1718Ter Nonsense Deleterious rs41293461 0.16% 
20 c.5263_5264insC 
5382insC 
(Q1756fs*74 )  
p.Ser1755?fs Frameshift Deleterious rs80357906 0.5% 
BRCA2 
6 c.1238delT 
1466delT 
(L413Hfs*16) 
p.Leu413Hisfs Frameshift Deleterious rs80359271 0.16% 
 7 c.631G>A V211I p.Val211Ile Missense Deleterious rs80358871 0.16% 
10 c.1496_1497delAG 
1724delAG 
(Q499Rfs*14) 
p.Gln499Argfs Frameshift Deleterious rs80359285 0.16% 
11 c.2808_2811delACAA 
3036delACAA 
(K936Qfs*21) 
p.Lys936_Gln937?fs Frameshift Deleterious rs80359352 0.16% 
11 c.4131_4132insTGAGA 1377insXG p.Asn1377_Thr1378?  
In Frame 
Insertion 
Deleterious rs80359429 0.16% 
11 c.5722_5723delCT 
5950delCT 
(L1908RfsX*2) 
p.Leu1908Argfs Frameshift Deleterious rs80359531 0.16% 
11 c. 6037A>T K2013X p.Lys2013Ter Nonsense Deleterious rs80358840 0.3% 
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14 
c.7008-2A>T IVS13-2A>T - 
Intervening 
Sequence 
Deleterious n.r.
2
 0.16% 
22 c.6486_6489delACAA 
6714del4 
(K2162fx) 
p.Lys2162_Gln2163?fs Frameshift Deleterious rs80359598 0.16% 
Cont. table 3: Causative BRCA1 and BRCA2 mutations found into analyzed population. 1Human genome variation society nomenclature, 
2
n.r. as not reported into NCBI databases. 
 
 
 
 
Table 5.  BRCA1 and BRCA2 unreported new variants. 
Gene Exon HGVS
1
 cDNA 
BIC 
Designation 
HGVS
1
 
Protein 
Mutation 
Type 
Clinically 
important 
(BIC) 
Ref. number 
NCBI 
Time 
Observed and 
allelic 
frequency 
Bioinformatic
predicted 
effect 
BRCA1 11 c.2811G>A K397K p.Lys397Lys Synonymous n.r.
1
 n.r.
1
 1 – 0.16%  - 
 11 c.3514C>T E1172X p.Glu1172Ter Nonsense n.r.
1
 n.r.
1
 2 – 0.3% Deleterious 
14 c.4481A>G E1494G p.Glu1494Gly Missense n.r.
1
 n.r.
1
 1 – 0.16% Benign 
19 c.5237A>C H1746P p.His1746Pro Missense n.r.
1
 n.r.
1
 1 – 0.16% Deleterious 
21 c.5406+2T>C IVS22+2T>C - 
Intervening 
Sequence 
n.r.
1
 n.r.
1
 1 – 0.16% Deleterious 
BRCA2 11 c.6567C>T N218N p.Asn218Asn Synonymous n.r.
1
 n.r.
1
 1 – 0.16% - 
 18 c.8299C>T P2767S p.Pro2767Ser Missense n.r.
1
 n.r.
1
 1 – 0.16% Deleterious 
Highlighted variants are confirmed by functional studies or in vitro assays.  
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Figure 14. Genealogy of the family carrier of the c.5266dupC BRCA1 deleterious 
mutation. Genetic testing allowed the identification of a healthy mutation carrier. 
Starting from these findings, the carrier and also her children can start a prevention 
program designed ad hoc to prevent the onset of the disease or to fight against cancer 
with personalized medicine, in order to perform a better management of surgery and of 
drug treatments. 
 
4.1. Synonymous and missense non deleterious variants 
Moreover, several detected variants are still unknown and not previously 
described in public databases (Table 5). All these novel variants were not found 
in all other alleles analyzed into our population and are on going to insertion into 
the BIC database. Among these variants there are: 2 synonymous variants, 
c.6567C>T N2189N and c.2811G>A K937K, and 1 missense variant, the 
c.4481A>G E1494G.  All of them were predicted by SIFT as benign and without 
clinical significance. Synonymous variants were found in women with positive 
familial history but affected by benign breast diseases. Instead, the not deleterious 
variant was found in a woman affected by early-onset BC. Despite these variants 
seem to be harmless from the first bioinformatic predictions, other insights are 
needed to understand their role into disease, also because they were not found into 
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healthy alleles. In this regard, several synonymous variants that were previously 
annotated in BIC like polymorphisms, were lately classified as VUSs. These 
evidences strongly suggest that also synonymous variants need more 
investigations, and that cannot be considered merely with no clinical significance. 
 
4.2. Double and triple mutations 
One nonsense mutation, c.3514C>T p.E1172X, not previously reported 
and predicted deleterious, causing a premature stop codon, was found in 2 women 
affected by BC, together with the mutation c.3491G>T p.S1164I localized on 
BRCA1 gene and previously described (Di Cecco 2009), even if annoted yet into 
databases. In addition, one of these patients resulted carrier also of the BRCA2 
stop codon c.9976A>T K3326X (largely described below). This is a very 
interesting case of triple mutation, detected for the first time into our population. 
The effect of the E1172X BRCA1 mutation could cover the effect of the S1164I 
missense one in the same exon, causing anyway the production of a truncated 
and/or non functional BRCA1 protein; nevertheless, the K3326X BRCA2 variant, 
causes a further stop codon that probably alters the BRCA2 function too. This 
cumulative effect could be dramatic for the functionality of BRCA1-BRCA2 
pathway leading the severe phenotypic effects shown by the patient.  
Furthermore, one more woman was found to carry a double mutation:  
c.631G>A p.V211I and c.7008-2 A>T IVS13-2 A>T, both localized on BRCA2 
gene. In this case, each mutation found in the patient was previously reported but 
never both in the same woman. Nevertheless, was not possible to build the 
genealogy of this patient’s family, neither of the triple mutation carrier’s family, 
to confirm the mutation into other subjects given that their relatives did not accept 
to undergo genetic testing. 
Every woman carrier of double mutations was affected by early-onset and 
bilateral BC and had a positive family history for BC and other cancers. The triple 
mutation carrier woman was affected by ovarian cancer too. These very 
aggressive phenotypes  probably depend of the cumulative effect of two mutations 
that could severely reduce the protein function. These evidences strongly suggest 
the pathogenetic effects of the new variant added to the reported ones. The same 
mutations were confirmed by Sanger sequencing in several relatives of patient’s 
family. These data allowed us to build, when it was possible, the genealogical 
three and to perform the linkage analysis of mutations (Fig. 15).  
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Figure 15. Genealogy of the family carrier of the double deleterious mutations 
c.3491G>T p.S1164I and c.3514C>T p.E1172X. These double mutations were found 
for the first time both localized on the same gene, following the inheritance showed in the 
analyzed family. 
 
In the future, will be interesting to test the biological effect of these double and 
triple mutations through functional and in vitro assays, to better understand the 
BRCA1/BRCA2 mutations cumulative effect on disease onset and development. 
One more future aim will be to collect more informations about the family 
through the relatives genotyping, in order to build genealogical trees and to 
perform a detailed linkage analysis of mutations.  
 
4.3. The c.5237A>C p.H1746P missense variant 
The c.5237A>C p.H1746P missense variant, was identified in a healthy 
patient belonging to a family with several cases of oncological diseases and, in 
particular, the mother was affected by BC. The variant is localized in the BRCA1 
C-terminal region, at the BRCT domain level; this domain is important for the 
binding of BRCA2 and other proteins, like Abraxas, CtIP and BRIP1, during the 
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DSBR pathway activation. The tandem BRCT domains of BRCA1 and MDC1 
facilitate protein signaling at DNA damage foci through specific interactions with 
serine-phosphorylated protein partners. Starting from these findings, the amino 
acidic change caused by the variant probably hampers the BRCA1/BRCA2 
complex functions.  
The first bioinformatic predictions through SIFT and PolyPhen-2 tools, describe 
the variant as deleterious. In particular, this mutation is predicted by PolyPhen-2 
to be possibly damaging with a score of 0.834 (sensitivity 0.84, specificity 0.93). 
This result derives from HumanDiv index, that is the preferred model for 
evaluating rare alleles, dense mapping of regions identified by genome-wide 
association studies and analysis of natural selection. Instead, the same variant 
resulted benign according to HumanVar index (score 0.177, based on sensitivity 
of 0.89 and specificity of 0.73), that is a model preferred for diagnostics of 
Mendelian diseases. This model requires distinguishing mutations with drastic 
effects from all the remaining human variations, including abundant mildly 
deleterious alleles (Fig 16).  Results from multiple sequence alignment, showed 
that the amino acidic residue changed by variation is not much conserved among 
species; this could justify the prediction of benignity made from the software 
(Fig.17).   
 
 
 
 
Figure 16. Prediction of pathogenicity of the c.5237A>C p.H1746P missense variant, 
performed by PolyPhen-2 tool. 
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Figure 17. Multiple sequence alignment variant derived from PolyPhen-2 software. 
In this picture are shown only the first alignments derived from the software: when the 
alignment proceeds among species becomes clear that the residue is not much conserved. 
  
 
 
 
 
In addition, the analysis performed by SIFT, predicted the variant as damaging 
(Fig. 18). 
 
 
Figure 18. Prediction of pathogenicity of the c.5237A>C p.H1746P missense variant, 
using SIFT computational approach. 
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Further predictions were performed by Database of human missense variants 
mapped to 3D protein structures (MSV3d) bioinformatic tool. The analysis 
showed that the variant causes protein size and charge decreases, plus polarity and 
hydrophobicity reductions, strongly supporting the hypothesis that the mutation 
can alter the protein folding and interaction with other protein complexes. 
However, is still not clear if these alterations can really hamper the DBSR 
processes.  
Moreover, this variant was analyzed also using PMut software 
(http://mmb2.pcb.ub.es:8080/PMut/) that classified the variation as pathological 
with a score of 0.976 on 1, which corresponds to the closest pathogenicity score.  
Starting from these assumptions, other studies are needed to confirm the missense 
variant’s role, to understand if it could be considered as deleterious or merely as a 
“polymorphism”.  
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4.4. The Pro2767Ser BRCA2 DNA-binding site missense variant 
 
 
The Pro2767Ser (c.8299C>T p.P2767S) missense variant, falling in the 
exon 18 of the BRCA2 gene, was identified in a young woman (28 years at the 
time of diagnosis) affected by breast fibrocystic dysplasia. In her family, at the 
time of the analysis, were not present other relatives affected by BC or by other 
cancers. Thus, it seems to be a sporadic breast disease.  
The BRCA2 DNA-binding domain contains a helical domain (H), three 
oligonucleotide binding (OB) folds and a tower domain (T), which may facilitate 
BRCA2 binding to both single-stranded DNA and double-stranded DNA (Roy 
2011). The unreported variant is localized in the oligonucleotide binding domain 2 
(OB2), into the tower domain. The substitution of the Proline residue with the 
Serine one generates polarity and hydrophobicity increases, suggesting the 
occurrence of folding changes into protein structure and in particular into the 
DNA binding domain. The mutant residue, located at the DNA binding site of 
BRCA2 protein as described before, probably interferes with the DNA binding, 
altering the HR and the DSBR processes in which this protein is involved. In 
particular, conformational changes caused by mutation in this important domain, 
could prevent the RAD51 and other repair proteins complexes binding, strongly 
hampering the damage response processes.  
Bioinformatic evaluations were performed using SIFT and PolyPhen-2 
computational approaches and confirmed by “Database of human missense 
variants mapped to 3D protein structures”too. Therefore, the first bioinformatic 
predictions of the variants showed a strong probability of pathogenicity, 
classifying that as deleterious (Fig. 19-23).  
 
 
 
 
Figure 19. Prediction of pathogenicity of the Pro2767Sser missense variant, 
performed using PolyPhen-2 tool. 
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Moreover, the amino 2767 acidic residue changed by variation resulted highly 
conserved among species, strongly supporting the hypothesis of a harmful 
mutation effect (Fig. 20). 
 
 
 
 
 
 
Figure 20. Multiple sequence alignment derived from PolyPhen-2 software. 
Software results show that Proline residue interested by variation is highly conserved 
among species.  
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Figure 21. 3D Visualization of residue Pro2767 interested by variation, resulting 
from PolyPhen-2 software.  
 
 
 
 
 
 
 
Figure 22. Prediction of pathogenicity of the Pro2767Ser missense variant, using 
SIFT computational approach. 
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Figure 23. Prediction of pathogenicity of the Pro2767Ser missense variant derived 
from MSV3d tool. 
 
 
 
 
Starting from these evidences, the last 2500 nucleotides of BRCA2-
10921bp-cDNA were cloned into a pRc/CMV vector (Fig.24), under the complete 
translation started sequence to assure the production of the mutant proteins. This 
DNA fragment contained the DNA binding sites, the nuclear localization 
sequence and one of the RAD51 binding regions. The Not I and Apa I enzymes 
were chosen because of their capability to recognize polylinker sequence sites and 
because they do not cut into BRCA2 selected sequence. In this way, into cloning 
primers were inserted Not I in forward and Apa I in reverse sequence in order to, 
first, amplify the target 2500bp BRCA2 sequence and, second, to create a 
fragment that was made up of restriction enzyme sites on its 5’ and 3’ ends. 
Through enzymatic digestions of amplicons were created blunt ends DNA 
fragments that were subsequently ligated into the pRc/CMV vector. Plasmids 
were transformed into bacterial cells and, after propagation, were purified through 
midi-prep plasmids preparation procedures.    
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Figure 24. PRc/CMV vector used for BRCA2 cDNA cloning. Between T7 and Sp6 
sequences, fragments were cloned into the Apa I/Not I restriction enzymes sites. The 
constructs were cloned in frame under the vector CMV promoter and using an initial 
ATG with the complete translation started sequence, including the Kozak consensus 
sequence, to assure the translation of the mutant proteins. 
 
 
On the wt construct were performed two single-bases mutagenesis reactions, in 
order to obtain two different clones: one containing the analyzed missense 
mutation, and the second one, used as a positive control for the next assay, 
containing a known deleterious mutation. The c.8297delC Thr2766Fs mutation 
was used as control of missed DBSR. The single base deletion causes the loss of 
the translation frame, followed by the sequence shifting and the production of a 
truncated protein, characterized by the loss of about 180 amino acids. Since the 
cloning sequence started to p.2633 amino acid residue, the derived truncated and 
non functional protein was made up of only 133 amino acids (about 15kDa), 
showing loss of the C-terminus domain. Therefore, after several in silico 
translation predictions performed to test the expressions of proteins and to verify 
wheter or not the inserted translation sequence was correct, the wt fragment and 
the mutants were transfected in NIH-3T3 cells. BRCA2 mutant proteins 
expression levels were tested through Western Blot analysis. Nuclear proteins 
were isolated through performing 3 minutes of pulse sonication, as described 
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above, in order to break DNA-proteins bindings, to avoid the loss of protein 
linked to DNA and assuring their separation from chromatin. Lysates were 
quantized by Bradford assay and 50µg of protein were loaded on 8% and 12% 
polyacrylamide gels. The 390kDa endogenous BRCA2 protein was too large to be 
detected into performed gels and was not considered in these experiments. As 
shown in the pictures (Fig. 25a-b), a 95kDa mutant BRCA2 protein was 
expressed in cells contained wt and Pro2767Ser constructs, but Thr2766Fs deleted 
protein showed no signal. This because truncated protein was too short to be 
identified using an 8% but also a 12% gel. Furthermore, the used antibody 
recognizes the C-terminus domain, that was not present in the mutant of deletion. 
Transfections and Western Blot analysis were performed at least five times and in 
duplicate, showing the same results. These findings demonstrated the translation 
of cloning sequences and the proteins production.  
 
 
 
Figure 25a. Western Blot analysis of BRCA2 mutant proteins. Pictures show the 
results of two 8% polyacrylamide gels performed at same conditions and in duplicate. 
The arrows show the bands strictly under 100kDa, corresponding to BRCA2 mutants. 
Only wt and Pro2767Ser proteins were detected, but no signals for Thr2766Fs were 
found. Moreover, were detected several nonspecific signals belonging to shorter proteins. 
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Since they were not revealed into Mock lanes, probably represented BRCA2 mutant 
proteins degradation products. This protein instability is probably due to the structure of 
mutants, cloned without N-terminus domain that maybe causes translation problems or 
post-translational changes, leading to several shorter and likely non functional products. 
Actin (not shown) was used to normalize the amount of protein in different samples and 
as a control of loading. The presence of proteins, especially into Mock lanes, was verified 
using the Ponceau S staining (not shown) that demonstrated the presence of proteins into 
all lanes.  
 
 
Figure 25b. Western Blot analysis of BRCA2 mutant proteins. Results of 12% 
polyacrylamide gels show the detection of wt and Pro2767Ser proteins. Despite the gel 
conditions were more stringent, no signals Thr2766Fs were revealed. The arrow indicates 
the bands strictly under 100kDa, corresponding to BRCA2 mutants. Also in this case, 
were present bands of lower molecular weight not detected into Mock lanes. 
 
 
Subsequently, these mutant DNA sequences were trasfected into NIH-GS cells, 
containing constitutively the pDR-GFP plasmid, and previously trasfected with I-
SceI-ER plasmids too (Fig. 26). 
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Figure 26. DR-GFP/I-SceI system used for DSBR assay. The expression of I-SceI 
induces DSB. Gene conversion events are able to repair the double strand break induced 
by I-SceI by using the downstream 3′ GFP as donor by homologous recombination 
processes that allow GFP expression. 
 
Then, was evaluated the capability of mutation to interfere with the DSBR 
processes in cells using the DR-GFP/I-SceI experimental system (Richardson 
1999). Briefly, this system was capable to mimic the DNA double strand breaks 
and the damage repair by homologous recombination (HR). To this aim, were 
generated clones of NIH-3T3 cells stably transfected with a DNA construct (DR-
GFP) containing two non-functional GFPs. The upstream (5’) GFP is under the 
control of the β-actin gene promoter and contains a single recognition site for the 
I-SceI endonuclease. Considering that no I-SceI sites are present in mammalian 
genomes, the expression of this enzyme results in generation of single DNA DSB 
only at DR-GFP sites. Gene conversion events are able to repair the double strand 
break induced by I-SceI by using the downstream 3’GFP as donor. The upstream 
5’ GFP contains 2 in-frame stop codons that cause the end of translation, thereby 
inactivating the gene. The downstream (3′) GFP is inactivated by upstream and 
downstream truncations, leaving only about 500 bp of the GFP sequence. The 
recombination event leads to the reactivation of the GFP gene (Fig. 26). Thus, 
when NIH-GS cells were transfected with the I-SceI plasmid, nuclear 
translocation results in DSBs generation. Homologous recombination repair in 
this system induces intra chromosomal gene conversion leading to the reactivation 
of the 5’ GFP gene. Indeed when the DSB is correctly repaired the 5’ GFP gene’s 
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frame is restored, allowing GFP expression. In this way, the cells where a 
successful repair takes place, express a functional GFP. The extent of repair can 
be measured by counting GFP positive cells by FACS.  
For this work an I-SceI-ER expression vector  was generated, in which the 
I-SceI cDNA is fused in frame with the cDNA fragment encoding the hormone-
binding site of the estrogen receptor alpha (ERα) (Stante 2009). The stable clones 
NIH-GS bearing DR-GFP were trasfected with I-SceI-ER and treated with 4-OH 
tamoxifen. When NIH-GS cells were treated with tamoxifen, the I-SceI-ER 
nuclear translocation results in DSBs generation with consequent DSBR and GFP 
emission.   
Based on concept that BRCA2 is involved in HR repair processes, in the proposed 
system, because mutant proteins were cloned without N-terminal portion and 
cannot operated normally, had to act in a dominant negative manner. The 
constructs, cloned as described above, led the production of a truncated and non-
functional BRCA2 proteins. Assuming that the tested mutations fall in the DNA-
binding site, performing the experiments only the capability of mutant proteins to 
bind DNA and to compete with endogenous BRCA2 protein was considered. 
Therefore, DNA repair efficiency in NIH-GS cells was measured by counting the 
percentage of GFP-positive cells after the transfection of I-SceI-ER plasmid into 
cells, previously transfected with BRCA2 clones, and 48 hours after their exposure 
to tamoxifen, which activates I-SceI ER.   
FACS results showed that cells transfected with positive control mutation 
(Thr2766Fs) and with investigated mutation (Pro2767Ser) appeared able to repair 
DNA damage, not avoiding the DNA binding of the endogenous BRCA2 proteins 
(Fig. 27a-e). On the other hand, in cells trated with the wt construct the DNA 
binding of the endogenous BRCA2 should have been avoided though a 
competition for the DNA-binding sites, preventing the GFP emission. In this case 
GFP emission was comparable among samples: in NIH-GS cells treated with 
Thr2766Fs and  Pro2767Ser the number of GFP positive cells was 2.0% and 1.7% 
respectively, showing that the pathogenetic effect of new mutation was 
comparable to the mutant of deletion, probably because Pro2767Ser makes 
BRCA2 incapable to bind DNA in the same way of Thr2766Fs. Similarly, cells 
transfected with Mock (empty vector without BRCA2 construct) showed about the 
same pattern of GFP emission (2.0%) and, accordingly, the same DSBR by HR in 
the cells where I-SceI-ER was activated by tamoxifen. NIH-GS cells treated with 
wt BRCA2, instead, showed a massive apoptotic effect. All cells were counted 
before the FACS analysis: wt cells, after 48h of tamoxifen induction, were only 
180,000/ml while Thr2766Fs, Pro2767Ser and Mock cells were counted over 
800,000/ml (exemplifying numbers deriving from one experiment,  starting to the 
same number of cells plated before transfections). Whereby, GFP emission 
revealed in wt cells (0.9-1.2%) was due only to the percentage of cells that did not 
acquired exogenous BRCA2 gene and did not expressed BRCA2 mutated proteins. 
These results were confirmed by fluorescence microscopy analysis that showed 
GFP emission particularly in Thr2766Fs, Pro2767Ser and Mock cells but 
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relatively revealed in wt cells too (Fig. 28a-d). All cells with a wt BRCA2 
successful transfection, expressing mutant proteins, were conducted to apoptotic 
processes, probably caused by the effects of several degradation products derived 
from mutants  (and because all the different-length-truncated BRCA2 proteins 
could compete with endogenous BRCA2 for DNA binding) added to the loss of 
repair efficiency. However, GFP emission revealed in wt cells seems wrongly the 
same of the other samples if is not considered the percentage of cells that survive 
to DNA double strand breaks and that repair DNA damage only because they do 
not express mutant wt BRCA2. 
 
 
 
 
Figure 27a. Measurement of repair efficiency in NIH-GS cells by FACS analysis. 
The figure shows the GFP emission of NIH-GS cells treated with wt BRCA2 construct. 
As largely described above, the percentage of GFP emission seems to be similar, or 
slightly lower then the other samples. Whereby, GFP emission revealed in wt cells was 
due only to percentage of cells that did not acquired exogenous BRCA2 gene and that 
survive correctly repairing DNA, as shown by GFP emission. Conversely, the remaining 
percentage of cells shows a massive apoptosis probably due to the several degradation 
products effects derived from mutants added to the loss of repair efficiency. This 
phenomenon could be explained by the great reduction in the number of cells 
(180,000/ml vs 800,000/ml). 
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Figure 27b. Measurement of repair efficiency in NIH-GS cells by FACS analysis. 
GFP emission of NIH-GS cells treated with Thr2766Fs BRCA2 deleterious mutation. The 
extent of repair is demonstrated by the percentage of GFP emission, suggesting that 
mutant BRCA2 protein cannot bind DNA and cannot compete with endogenous BRCA2 
that allow the normal repair efficiency. 
 
 
 
Figure 27c. Measurement of repair efficiency in NIH-GS cells by FACS analysis. 
GFP emission of NIH-GS cells treated with Pro2767Ser BRCA2 novel variant. The 
percentage of GFP emission suggests that the mutant BRCA2 protein cannot bind DNA 
57 
 
and cannot compete with endogenous BRCA2, allowing the normal repair efficiency. The 
effect of this variant appears comparable to the deletion reported as surely pathogenetic.  
 
 
 
 
Figure 27d. Measurement of repair efficiency in NIH-GS cells by FACS analysis. 
GFP emission of NIH-GS cells treated only with empty vector, used as control. The 
extent of repair is revealed by the percentage of GFP emission, demonstrating that the 
system DR-GFP/I-SceI-ER works correctly after tamoxifen induction and allows the 
normal DSBR processes managed by endogenous BRCA2 protein.  
 
 
Figure 27e. Measurement of repair efficiency in NIH-GS cells by FACS analysis. 
GFP emission of NIH-GS cells treated with vehicle and not with tamoxifen. In this case, 
the system DR-GFP/I-SceI-ER was not activated, and was used as negative control. The 
58 
 
percentage of GFP emission represents the fluorescence background and does not 
originate from inducted biological effects.  
 
 
 
 
 
 
Figure 28a. Visualization of repair efficiency in NIH-GS cells by fluorescence 
microscopy. GFP emission of NIH-GS cells treated with wt BRCA2 construct. On the 
left is shown the image on bright field (10X): the cell morphology and the great number 
of in suspension cells show the massive apoptotic effect described before. On the right 
the image on GFP fuorescence: the GFP emission is very low and present only for cells 
that survive to apoptosis. 
 
 
 
 
Figure 28b. Visualization of repair efficiency in NIH-GS cells by fluorescence 
microscopy. GFP emission of NIH-GS cells treated with Thr2766Fs BRCA2 deleterious 
mutation. In the image on bright field (10X) cells appear more confluent than wt and 
more vital, the numer of in suspension cells was lower and comparable to cells trated with 
Pro2767Ser BRCA2 novel variant and empty vector (Mock). The percentage of GFP 
emission, in the right side of the picture, seems grater than wt cells.   
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Figure 28c. Visualization of repair efficiency in NIH-GS cells by fluorescence 
microscopy. GFP emission of NIH-GS cells treated with Pro2767Ser BRCA2 novel 
variant. Despite the GFP emission appeared low in all samples, the GFP revealed into 
these cells suggested that mutant BRCA2 protein does not compete with endogenous 
BRCA2. The effect appears comparable to the mutant Thr2766Fs. 
 
 
 
 
 
Figure 28d. Visualization of repair efficiency in NIH-GS cells by fluorescence 
microscopy. GFP emission of NIH-GS cells treated only with empty vector, used as 
control. The image on bright field (10X) demonstrates the cell viability and confluence. 
The percentage of GFP emission, on the right side of the picture, demonstrates that the 
system DR-GFP/I-SceI-ER after tamoxifen induction allows the normal DSBR processes 
managed only by endogenous BRCA2 protein.  
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The massive apoptotic effect in wt BRCA2 cells has been demonstrated 
using Apoptosis Assay Annexin V protocol, performed by flow-cytometry (Fig. 
29a-b and Fig. 30).  
Briefly, Annexin V is a member of a calcium and phospholipid binding family of 
proteins with vascular anticoagulant activity. Results from in vitro experiments 
indicate that it may play a role in the inhibition of blood coagulation by competing 
for phosphatidylserine (PS) binding sites with prothrombin. In healthy cells, PS is 
usually kept in the cytosolic side of the cell membrane. When a cell undergoes 
apoptosis, one of the earliest detectable indicators is the loss of membrane 
asymmetry. No longer restricted to the cytosolic part of the membrane, PS is 
translocated to the outer-leaf and becomes exposed on the surface of the cell (Van 
Engeland 1998). Using Annexin V-APC and Propidium Iodide (PI) reagents was 
possible to distinguishing two populations of dying cells from viable cells. Cells 
in the early stages of apoptosis with intact cell membranes and surface-exposed 
PS will stain positive for Annexin V-APC. PI is used to identify late apoptotic and 
necrotic cells, which have lost plasma membrane integrity. These cells are labeled 
with Annexin V-APC and Propidium Iodide. Live cells with intact plasma 
membranes exclude PI and remain unstained by the Annexin V-APC probe.  
 
 
Figure 29a. Measurement of Annexin V in NIH-GS cells by FACS analysis. 
Apoptosis found in wt BRCA2 cells at 24h after tamoxifen induction. In order to 
differentiate late to early apoptotic stages, PI+ indicates necrotic or late apoptotic cells, 
while PI- are cells that still maintain plasma membrane integrity but that have started the 
apoptotic processes. 24h after induction of DBS, cells started to die slowly probably 
because they cannot support replicative processes or doing HR without the binding of 
endogenous BRCA2 to DNA. 
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Figure 29b. Measurement of Annexin V in NIH-GS cells by FACS analysis. The 
figure shows the apoptosis in cells treated with wt BRCA2 protein 48h after tamoxifen 
induction: cells demonstrated a large apoptotic effect, and only few viable cells were 
detected.  
 
 
 
Figure 30. Measurement of Annexin V in NIH-GS cells by FACS analysis. Apoptosis 
in cells trated with Pro2767Ser BRCA2 novel variant, 48h after tamoxifen induction. 
Percentages of PI internalization showed that the apoptotic effect of the variant was lower 
than the wt and comparable to fisiological effects of several transfections on cells 
viability. 
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Considering these very preliminary results, Pro2767Ser novel mutation 
seems to be pathogenetic: the single nucleotide substitution allows an aminoacidic 
change that can strongly compromise the DNA binding of BRCA2 protein and, 
consecutively, the repair efficiency. These data reflected and confirmed all 
bioinformatic predictions.  
Despite that, other investigations are necessary to better understand the 
role of this variant. In particular, is important to verify wheter or not BRCA2 
mutant proteins really do not bind DNA, or if the repair is compromised by other 
mechanisms, still not clear. For this reason, on this variant other experiments are 
ongoing: in the near future, on one hand, several chromatin immunoprecipitation 
(ChIP) experiments will be performed to confirm the missed DNA binding. On 
the other hand, will be demonstrated, at first, how wt BRCA2 mutant proteins 
determine a toxic apoptotic effect on cells that expressed the exogenous construct, 
and second, will be explored if Pro2767Ser variant can hamper the formation of 
nuclear foci because of the RAD51 and related proteins complexes recruitment 
failure.  
In conclusion, further analysis are needed to understand the Pro2767Ser 
variant effect on cancer. However, patient’s disease that seemed to derive from 
sporadic and non-genetic causes should be connected to a BRCA2 germline 
mutation and the search of the Pro2767Ser variant should be performed in the 
patient’s relatives before the onset of probable futures oncologic diseases.  
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4.5. The BRCA1 c.5406+2T>C IVS22+2T>C splice variant 
 
A new splice variant, namely c.5406+2T>C IVS22+2T>C, was identified 
in heterozygous status. Predicted as deleterious by Human Splice Finder and 
NetGene2 that showed the loss of a canonic donor splice site localized at position 
+2 in the intron 21 of BRCA1 gene, this splice variant was evaluated by the 
functional studies reported below. The variant was found in a 60 years old 
woman, affected by breast cancer, showing the presence of several cases of cancer 
into her families (Fig. 31). The patient’s mother and one sister are the only 
relatives still alive and to date they are not affected by BC or other cancers. 
Despite that, they did not undergo to genetic testing. The presence of the variant 
into the family cannot be confirmed because all affected relatives are died. This 
evidence could suggest the probable role of the variant. 
 
 
 
 
Figure 31. Genealogy of the patient’s family carrying the novel c.5406+2T>C splice 
mutation in BRCA1 gene. A patient’s nephew (III.1) died for early-onset breast cancer 
and her sister (not shown) was, to date, affected by BC. 
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Splicing is a process in which mRNA is modified after transcription. It allows the 
introns removal and the union of exons to form mature mRNA, ready for 
translation into protein. The gene splicing can be easily affected by mutations in 
the sequence surrounding the splice site junction, leading to alternate splicing and 
thus adversely affecting the translated protein. Indeed, when a mutation occurs 
into a splice site and contributes to the loss or to the gain of a donor or an acceptor 
splice site, the normal splice mechanism is altered and leads to exon skipping or 
intron retention events.  
Bioinformatic predictions suggest that the novel splice variant IVS22+2T>C 
produces the retention of the intron in which is localized (Fig. 32), with probably 
consequences on mRNA maturation.    
 
 
                
                 Exon 21                                                            Exon 22                 BRCA1 gene 
 
 
 
 
 
Figure 32. Definition of scored intron retention events. Gray rectangles represent 
exons of BRCA1 gene, and mRNA. Exon/intron boundaries are marked by dotted lines. 
 
To test the pathogenicity of this splice variant and to confirm the bioinformatic 
predictions, patient RNA was retrotranscripted together with two control RNAs: a 
woman affected by BC and a woman with strong familiar history of cancer but not 
affected, totally screened for BRCA1/2 mutations and resulted negatives. The 
resulted cDNAs were amplified using different pairs of primers designed ad hoc. 
To demonstrate the presence of the target BRCA1 cDNA and to avoid the 
amplification of gDNA contamination, a pair of primers was designed to anneal 
on flanking cDNA exons. One more was designed to cover about 470bp of the 
retained intron, to show the presence of this one only in mutated cDNA. Finally, 
to demonstrate that the result of the latter amplification do not derive from gDNA, 
another PCR reaction using a forward primer annealing a cDNA region and a 
reverse primer complementary to the retained intronic region was performed: only 
the mutated cDNA has given positive amplifications (Fig. 33 a-b). 
BRCA1 mRNA 
  
Retained Intron 21 
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Figure 33a. PCR amplification confirms of splice variant, agarose 2%. The 
amplifications on BRCA1 cDNA with primers that give a product of about 870bp, showed 
the same profile for mutated cDNA and for controls (not shown). The retained intron 
produced, for mutated allele, two amplicons: one of 870bp and one of more than 1400bp, 
not amplifiable through used PCR conditions and not visible in the first gel. Therefore, on 
mutated and controls cDNAs was performed a second amplification using a pair of 
primers covering a 470bp intronic region. In the picture are shown the amplification 
results: in the lane 1 was loaded a control cDNA in which there was no intronic retention 
with consequential no amplification; in the lane 2 was loaded the mutated cDNA with 
intronic retention, in the lane 3 was loaded an duplicate of sample loaded into lane 2, in 
the lane 4 was loaded a gDNA used as positive control of amplification.  
 
 
Figure 33b. PCR amplification confirms of splice variant, agarose 1%. In the lane 1-4 
the results of amplification of the 470bp retained intron (also described above): in the 
lanes 1 and 2 were loaded the controls cDNA with no retention, in the lane 3 was loaded 
the mutated cDNA with the intronic sequence that gave positive amplification, and in the 
lane 4 was loaded the gDNA used as positive control of amplification. The amplification 
performed using a forward primer covering a cDNA region and a reverse primer covering 
the retained intronic region produced a 1417bp amplicon only on mutated cDNA. In the 
lanes 6 and 7 were loaded the control cDNAs that gave no products, in the lane 8 was 
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loaded the patient mutated cDNA and in the lane 9 was loaded a gDNA that gave only 
aspecific amplicons. The aspecifics bands were analyzed by Sanger sequencing after 
extraction and purification from gel. In the lane 10 were loaded 7µl of Ladder 1Kb 
(BioLabs).  
 
In addition, two restriction maps were performed: one on the retained 
intron sequence and another one on a portion of the cDNA sequence amplified by 
designed primers described before. From the analysis and the comparison of these 
restriction maps, the NcoI restriction enzyme was chosen because of its capability 
to recognize the cleavage site C|CATGG present only in the intronic sequence and 
not in the the BRCA1 cDNA amplified region. The enzyme, when recognizes its 
cutting sequence, produces two fragments on mutant cDNA: one of about 1100bp 
and another of about 280bp. Given that the patient’s variant is in heterozygosity, 
the two alleles show different digestion patterns in the same lane. After the 
enzymatic digestion of the in exam cDNA and of controls, DNA fragments were 
analyzed by DNA Chip 1K (BioRad). The analysis showed different digestion 
patterns among samples: only the mutated cDNA was cutted by NcoI, while the 
controls cDNAs profiles appeared the same of the uncut cDNA using as ulterior 
control. In this way, was ultimately demonstrated the intronic retention (Fig. 34-
39). 
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Figure 34. Virtual gel report from 1K DNA Assay.  In the lane L was loaded the DNA 
molecular weights ladder, from 15bp to 1500bp; in the lane 1 was loaded the the 
amplified cDNA digested by NcoI and carrier of the mutation; in the lane 2 was loaded an 
amplified control cDNA digested by NcoI; in the lane 3 was loaded a gDNA digested by 
NcoI using as positive control of the enzyme cutting; in the lane 4 was loaded the 
amplified not cutted cDNA.   
 
 
 
Figure 35. Ladder peaks and ladder lane from 1K DNA Assay.  
Area under each peak corresponds to specific quantity of ladder and is useful for the 
comparison of fluorescence of other samples in order to quantize them. 
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Figure 36. Sample 1 lane from 1K DNA Assay.  
The portion of 800bp cDNA carrying the mutation, was digested with NcoI enzyme and 
the product of the digestion was loaded into lane 1. In the picture are shown the lower 
marker and the upper marker that are the first and the last peaks, useful to normalize 
fluorescence as internal control of quantification. The peaks resulting from the sample are 
one of 878bp, corresponding to uncut cDNA derived from the wt allele, and another one 
of 1105 corresponding to mutated allele cut by the enzyme. The peak showing the 280bp 
fragment was too low to be detected in fluorescence (according to the detection limits of 
the used assay) if compared to the ladders fluorescence, but it can be revealed in the 
virtual gel (indicated by red arrow). The patient’s variant is in heterozygosity and two 
alleles show different digestion patterns in the same lane.  
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Figure 37. Sample 2 lane from 1K DNA Assay.  
The control wt cDNA amplified with primers that produce an amplicon of about 800bp, 
digested with NcoI enzyme: the product of the digestion was loaded into lane 2. Only the 
peak of 884bp, corresponding to uncut wt cDNA appeared into this lane. 
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Figure 38. Sample 3 lane from 1K DNA Assay.  
A gDNA was digested by NcoI as positive control of enzymatic cleavage, and the 
digestion product was loaded into lane 3. Several fragments of different molecular 
weights were presents, and appeared after the upper marker, showing many enzymatic 
cuts and demonstrating the enzyme functionality. 
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Figure 39. Sample 4 lane from 1K DNA Assay.  
The control wt cDNA amplified with primers that produce an amplicon of about 800bp, 
was loaded into lane 4, without enzymatic digestion. Only the peak of 876bp, appeared 
into this lane in a concentration more higher than upper ladder. This was the same profile 
of the wt digested cDNA. 
 
 
Despite other studies are needed to confirm the role of this splice variant, 
the positive amplifications present only in the cDNA carrying the mutation and 
not into the controls, and the restriction enzyme digestion patterns have 
demonstrated the bioinformatic predictions and the very probable pathogenicity of 
the found variant. 
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4.6. Male breast cancer mutation carriers 
 
Furthermore, 2 men were found to be carrier of a BRCA1/BRCA2 causative 
mutation. One, affected by early-onset breast cancer, carries the 
c.2808_2811delACAA  p.K936Qfs*21 frameshift mutation in BRCA2 gene: men 
affected by BC and carrying a causative BRCA2 mutation are very rare if 
compared to man carrying a causative BRCA1 one, and the risk for these carriers 
to develop oncologic diseases is very high. In the patient’s family there are a lot of 
cases of cancers, especially ovarian, normally characterized by BRCA1 mutations; 
in addition, is interesting to underline that the inheritance of mutation seems to 
derive from paternal side (Fig. 40).   
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Figure 40. Genealogy of the male patient’s family carrying the 
c.2808_2811delACAA p.K936Qfs*21 frameshift mutation in BRCA2 gene. Genetic 
testing allowed the identification of two healthy carriers, one of them was a man. The 
transmission of the variant seems to derive from the paternal side.   
 
 
A causative BRCA1 mutation was found into a healthy carrier belonging to a high-
risk family that carries the c.5431C>T p.Q1811X nonsense mutation. In this 
family, the analysis started from the aunt, that submitted the analysis in the past, 
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she was carrier of the same mutation, and died for ovarian cancer. The patient’s 
mother died for colon cancer and no genetic information about her were available 
(Fig. 41). 
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Figure 41. Genealogy of the male patient’s family carrying the c.5431C>T p.Q1811X 
nonsense mutation in BRCA1 gene. The mutation was searched into two brothers and 
only the man resulted carrier.  
 
It is not rare to find a man affected by BC carrying a germline mutation, 
especially with strong familiarity for BC and/or other cancers. Indeed, further 4 
men were identified to be carrier of mutations in several high-risk families. All 
these men were (to date) healthy carriers, not affected by BC and/or others 
disease.  
Male carriers of mutations in BRCA1 or BRCA2 are susceptible to cancer; 
however, their risks remain poorly understood and their optimal clinical 
management has not yet been defined. Male BRCA1 mutation carriers show an 
increased risk of prostate and breast cancer. Evidence supporting increased 
susceptibility to colon cancer is limited to women (as demonstrated in our 
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patient’s BRCA1 carrier family, in which the mother of proband died for colon 
cancer). In contrast to women, who have a greater lifetime risk of cancer with 
mutations of the BRCA1 gene, BRCA2 is the more important gene for men. The 
BRCA2 spectrum of cancers is wide and some studies have reported that the 
overall cancer risk for male BRCA2 carriers exceeds the risk for female carriers. 
In particular, the relative risk for male BRCA2 mutation carriers is higher before 
age of 65 years, largely attributable to breast, prostate, and pancreatic cancers. 
BRCA2 mutation carriers are also at risk of stomach cancer and melanoma (of the 
skin and eye). Male breast cancer is a characteristic element of the BRCA2 
phenotype (Wooster 1994, Tonin 1995). Breast cancer accounts for less than 1% 
of all cancers in men (The U.S. Cancer Statistics Working Group 2002). The 
lifetime risk of male breast cancer in BRCA2 mutation carriers is approximately 
80 to 100 times higher than in the general population (Thompson 2001), and 
BRCA2 mutations account for roughly 15% of all male breast cancers. For BRCA2 
mutation carriers, the risk of male breast cancer before age 80 years was recently 
estimated to be 6.9% (Thompson 2001). Generally, men with breast cancer 
present at a more advanced stage than women and have a poorer prognosis (SEER 
Database 2003). Knowledge of mutation status for men in BRCA2 families may 
be useful for risk assessment and for prevention, as greatly reported by Liede 
(2004). 
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4.7. The BRCA2 stop codon c.9976A>T K3326X 
 
 
Furthermore, the BRCA2 stop codon human variant c.9976A>T K3326X, 
was found into an affected woman, with a two primary breast cancers history, 
belonging to a family characterized by many cases of cancers (Fig. 42). 
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Figure 42. Genealogy of family carrying the K3326X variant. 
The family shows a cluster of tumors. In particular, the patient had six brothers. Three of 
them were affected by a single neoplasia: one had a lung cancer at age 53 years, one had a 
bladder cancer at 78 years, and the third a throat cancer at 64 years. Two other brothers 
had been affected by two primary cancers each: one had oesophagus and lung cancers at 
65 and 71 years respectively (still alive), and the other jaw and bladder cancers at the age 
of 52 and 65 respectively. The other four brothers died as a consequence of their disease. 
The sixth brother (currently 60 years old) has a negative history for cancer, however his 
daughter died from brain cancer at 4 years. Moreover, an uncle of the patient died from 
lung cancer. Finally, the daughter of the brother affected by bladder cancer has a history 
of ovarian cancer diagnosed at 35 years and has recently been diagnosed with rectal 
cancer (56 years) with hepatic lesions. 
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This variant was previously described as a polymorphism, also in data 
banks of breast cancer-predisposing mutations (Mazoyer 1996). Despite several 
functional studies about this variant appeared inconclusive, and it seemed 
unrelated to BC, a number of studies have suggested that it may increase the risk 
of other oncological diseases (Morimatsu 1998, Howlett 2002, Martin 2005, Rudd  
2006, Akbari  2008). Although our patient’s history strongly suggests the 
presence of familial neoplasias, the molecular analysis of BRCA1 and BRCA2 did 
not identify any causative mutation previously described. Instead, it revealed the 
BRCA2 K3326X variant, which causes a premature stop codon and the loss of 93 
amino acids at the protein’s C-terminus. The K3326X variant was identified in 
only 1 allele of 200 BC analyzed patients. This corresponds to a frequency of 
0.25% (calculate at the time of the patient’s genetic test).  
Furthermore, the variant was lately found into another patient of 39 years 
old, affected by BC and belonging to a family with several cases of breast, ovarian 
and other types of malignancies, in which no deleterious reported mutations were 
identified. Moreover, as described above, this variant was found into an HBOC 
patient already carrier of other mutations in BRCA1 gene. 
Given the above-mentioned reports (referred to manuscript attached to the 
thesis, D’Argenio 2014), caution should be exerted in considering BRCA2 
K3326X merely a benign polymorphism, as codified in the BIC database; rather 
we open the debate that it may be considered a pathogenetic variant. 
 
 
 
4.8. VUSs and polimorphisms 
 
Moreover, several polimorphisms and 26 (15 localized in BRCA1 and 11 
in BRCA2) variants with unknown clinical significance (VUSs) were also totally 
detected (Tables 6-9).  
VUSs are mostly missense sequence variations without a definite role in 
carcinogenesis, thus representing a real clinical challenging. Indeed, in many 
cases they were found in women resulted negatives for BRCA1/2 causative 
mutations but affected by HBOC. These findings induce to pay more attention to 
these variants, and to not consider lightly such as benign polimorphisms. In 
general, a VUS is considered “benign” only when is found together with a 
causative mutation.   
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Table 6. BRCA1 polimorphisms.  
Gene Exon HGVS
1
 cDNA 
BIC 
Designation 
HGVS
1
 Protein 
Mutation 
Type 
Clinically 
important 
(BIC) 
Reference 
number NCBI 
BRCA1 11 c.2077G>A D693N p.Asp693Asn Missence No rs4986850 
 11 c.3113A>G E1038G p.Glu1038Gly Missense No rs16941 
11 c.3548A>G K1183R p.Lys1183Arg Missense No rs16942 
16 c.4837A>G S1613G p.Ser1613Gly Missense No rs1799966 
 
 
Table 7. BRCA1 VUSs.  
Gene Exon HGVS
1
 cDNA 
BIC 
Designation 
HGVS
1
 Protein 
Mutation 
Type 
Clinically 
important 
(BIC) 
Reference 
number NCBI 
BRCA1 
8 c.442-3_442-3delT IVS7-3delT - 
Intervening 
Sequence 
Unknown n.r.
1
 
 9 c.591C>T C197C p.Cys197Cys Synonymous Unknown rs1799965 
 
10 c.671-12_671+12delT IVS10+12delT - 
Intervening 
Sequence 
Unknown n.r.
1
 
11 c.1067A>G Q356R    p.Gln356Arg Missense Unknown rs1799950 
11 c.2082C>T S694S p.Ser694Ser Synonymous Unknown rs1799949 
11 c.2311T>C   L771L p.Leu771Leu Synonymous Unknown rs1694011 
11 c.2612C>A P871L p.Pro871Gln Missense  rs799917 
11 c.3119G>A S1040N p.Ser1040Asn Missense Unknown rs4986852 
11 c.1911T>C T637T p.Thr637Thr Synonymous Unknown n.r.
1
 
11 c.3418A>G S1140G p.Ser1140Gly Missense Unknown rs2227945 
11 c.3711A>G I1237M p.Ile1237Met Missense Unknown rs80357388 
13 c.4308T>C S1436S p.Ser1436Ser Synonymous Unknown rs1060915 
16 c.4837A>T S1613C p.Ser1613Cys Missense Unknown rs1799966   
78 
 
16 c.4843G>A A1615T p.Ala1615Thr Missense Unknown rs80356987   
 16 c.4956G>A M1652I p.Met1652Ile Missense Unknown rs1799967 
Cont. table 6: BRCA1 VUSs 
 
 
Table 8. BRCA2 polimorphisms.  
Gene Exon HGVS
1
 cDNA 
BIC 
Designation 
HGVS
1
 Protein 
Mutation 
Type 
Clinically 
important 
(BIC) 
Reference 
number NCBI 
BRCA2 10 c.1114C>A H372N p.Asn372Asn Synonymous No n.r.
1
 
 10 c.1365A>G S455S p.Ser455Ser Synonymous No rs1801439 
10 c.1151C>T S384F p.Ser384Phe Missense No rs41293475 
10 c.865A>C N289H p.Asn289His Missense No rs766173 
11 c.3396A>G K1132K p.Lys1132Lys Synonymous No rs1801406 
11 c.4563G>A L1521L p.Lys1521Lys Synonymous No n.r.
1
 
11 c.3807T>C V1269V p.Val1269Val Synonymous No rs543304 
11 c.5199C>T S1733S p.Ser1733Ser Synonymous No rs28897734 
11 c.4585G>A G1529R p.Gly1529Arg Missense No rs28897728 
11 c.5312G>A G1771D p.Gly1771Asp Missense No rs80358755 
11 c.6513C>G V2171V p.Val2171Val Synonymous No n.r.
1
 
14 c.7242A>G S2414S p.Ser2414Ser Synonymous No rs1799955 
27 c.9976A>T K3326X p.Lys3326Ter Nonsense No rs11571833 
Highlighted variant is annotated as SNP but we open the debate that it may be considered a pathogenetic variant; I found that in 3 patients 
affected by BC and belonging to a family with several cases of oncologic diseases. On 600 alleles of our population, this particular SNP 
shows an allelic frequency of 0.5%. 
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Table 9. BRCA2 VUSs.  
Gene Exon HGVS
1
 cDNA 
BIC 
Designation 
HGVS
1
 Protein 
Mutation 
Type 
Clinically 
important 
(BIC) 
Reference 
number NCBI 
BRCA2 10 c.865A>G N289D p.Asn289Asp Missense Unknown rs766173 
 10 c.1124C>T P375L p.Pro375Leu Missense Unknown rs80358409 
10 c.1909+12_1909+12delT 
IVS10+12delT - Intervening 
Sequence 
Unknown n.r.
1
 
11 c.2229T>C H743H p.His743His Synonymous Unknown rs1801499 
11 c.2971A>G N991D p.Asn991Asp Missense Unknown rs1799944 
11 c.3515C>G S1172W p.Ser1172Trp Missense Unknown rs80358600 
11 c.3824T>C I1275T p.Ile1275Thr Missense Unknown rs80358625 
11 c.5744C>T T1915M p.Thr1915Met Missense Unknown n.r.
1
 
14 c.7008-20A>G IVS13-20A>G  
Intervening 
Sequence 
Unknown rs81002903 
16 
c.7397C>T 
A2466V 
 
p.Ala2466Val Missense Unknown 
rs169547 
 
16 
c.7806-14T>C IVS16-14 T>C - Intervening 
Sequence 
Sequence 
Unknown 
rs9534262 
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Starting from the finding of a causative mutation into an at-risk family, 
relatives are subsequently subjected to the note mutation research. The subsequent 
analysis of the families of the mutation carriers, allowed the identification of the 
at-risk subjects that have been involved in surveillance programs of preventing 
health care, especially before the disease onset. Here is shown one representative 
family in which was found the causative mutation in a large number of healthy 
carriers starting only from the criteria that in the family there were many cases of 
cancers (Fig. 43). The first proband was tested by NGS screening and, when 
causative mutation was found, the same mutation was searched into the relatives. 
Identification of mutation carriers before the onset of the disease is a very 
important weapon for the prevention and the fight against HBOC.  
 
II.1
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I
II
II.5
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I.3
II.2
III.1
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II.6
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BRCA1
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Figure 43. Genealogy of a family carrying the c.3351_3352insT Q1118SfsX*4 
causative mutation in BRCA1 gene. The analysis started from the concept that the 
family had a strong positive history of cancers; indeed two women died for BC and a man 
for lymphoma. Causative mutation was searched by the NGS screening in one healthy 
relative (II.4) and was confirmed into one brother and in two nephews. Also in this family 
is possible to note the presence of male mutation carriers.  
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Therefore, results of genetic testing have a great decision-making role for 
what concern the surgery and the treatments for BC patient especially, but also for 
healthy carriers of causative mutations, considering that this is a very difficult 
medical aspect.   
Indeed, the relatively poor prognosis of young women with very-early 
onset breast cancer raises a critical question: should women diagnosed before the 
age of 40 be treated differently than older women? For example, should all very-
young women with invasive breast cancer receive chemotherapy, regardless of 
tumour size, grade or nodal status? A second question is whether or not women 
with very-early onset breast cancer are candidates for breast-conserving surgery. 
Given that no compelling data from randomized trials have shown that there is an 
inferior outcome for young women treated with breast-conserving surgery, 
compared to mastectomy, the arguments in favour of mastectomy are indirect: 
first, the risk of local recurrence is much higher for young women than for older 
women; second, the mortality rate for young women after a local recurrence is 
very high. This risk of contralateral breast cancer is also relevant, in particular if 
contralateral preventive mastectomy is being considered. Risk factors for 
contralateral breast cancer include young age at diagnosis, and the presence of 
BRCA1 or BRCA2 mutation.  
 However, for a 30-year-old woman with breast cancer, the 10-year 
cumulative risk of contralateral breast cancer is only about 5%. It has been shown 
that contralateral mastectomy reduces the incidence of contralateral breast cancer 
in women with a hereditary predisposition and in women at high risk, but there are 
few data on mortality benefit (Narod 2013). A third question is whether or not 
there is benefit from ovarian ablation that goes beyond that of chemotherapy and 
hormone therapy. In BRCA1 and BRCA2 carriers, oophorectomy is recommended 
to prevent cancer recurrence, contralateral breast cancer and new primary ovarian 
cancer, but in non-carriers there is less evidence in support of the procedure. 
 The Early Breast Cancer Trialists Collaborative Group study confirmed 
the benefit of chemotherapy in treating breast cancer in women diagnosed before 
the age of 50. Overall, the mortality rate was reduced by 38% with adjuvant 
chemotherapy (EBCTCG 2012). They also reported that the benefit of 
chemotherapy was present for very-young women with node-negative breast 
cancer and with small breast cancers. Young age was a risk factor for recurrence, 
but the adverse effect of age on survival was greatly attenuated in women treated 
with chemotherapy. Interestingly, this finding is analogous to the situation in 
BRCA1-associated cancers, wherein the adverse effect of a BRCA1 mutation is 
present only in women not treated with chemotherapy. The situation is easier for 
hormone receptor-negative cases, where there are fewer treatment options. For 
young women with receptor-positive cancer, alternates to cytotoxic chemotherapy 
include tamoxifen, ovarian ablation (surgical or chemical suppression) and in 
some cases, the addition of an aromatase inhibitor. Several studies suggest that for 
women with low-risk hormone receptor-positive disease, endocrine therapy might 
be as effective as cytotoxic chemotherapy. Accordingly, there is much interest in 
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preventing breast cancer. In this regard, recently, Fenretinide (4-
hydroxy(phenyl)retinamide; 4-HPR), a synthetic retinoid derivative, is emerging 
as a protective drug in BRCA1/2 mutation carriers women. Our group participates 
to a collaboration with IEO of Milan to test this drug on mutation carriers healthy 
relatives of BC patients, in order to understand the role of this “natural” drug on 
the disease onset during the next few years. 
Further, the argument for breast cancer awareness is more compelling. 
Currently, routine mammographic breast screening is not recommended for 
women under the age of 40. Nevertheless, if is accepted that BC should be 
diagnosed at the smallest possible size, and that tumor size is a good predictor of 
mortality, then reducing mean tumor size will have a beneficial effect on 
mortality. Breast self-examination is promoted throughout the world as an 
inexpensive alternative to mammography, if added to periodic preventive 
echographies.   
However, as greatly reported in medical literature, is still difficult to 
manage treatments of an HBOC mutation carrier patient.   
In this regard, lately, a little breast tumor with a good response to 
chemiopreventive treatment was found into a young patient (44 years old). 
Starting from these evidences, the patient was candidate only for a 
quadrantectomy. Meanwhile, she underwent genetic testing and resulted carrier of 
a BRCA1 causative mutation, in particular of c.3403C>T p.Q1135X. The rapidity 
of genetic result has leaded medical decisions to a total mastectomy and to a 
different and more aggressive pharmacological treatments, in order to better 
remove cancer and to avoid recurrence of pathology.  
These results assess the feasibility of a next generation sequencing approach for 
BRCA1/BRCA2 mutation detection to be included in a routine diagnostic 
workflow, because of speed and cost-sparing features of this recently developed 
methodology. 
Nevertheless, when genetic informations about patients are collected, 
management of genetic counseling is a very sensitive and difficult aspect. Women 
who carry a BRCA mutation are candidate for options of early and intensive 
surveillance, chemoprevention and prophylactic surgery. Oncologists and 
geneticists help women understand the risk that their BRCA status represents for 
them and their relatives. They also identify and address biopsychosocial factors 
that may foster women’s adherence to preventive and/or risk-reducing strategies, 
in order to reduce the morbidity and mortality associated with hereditary or 
familial cancers.  
Since the initial application of BRCA testing in research first, and subsequently 
also in oncology practices, scientists, physicians and bioethicists have consistently 
cared about the medical and psychosocial well-being of mutation carriers, and 
have cautioned the public about the limited predictive power of genetic testing, 
especially outside high-risk families, due to the relatively low gene penetrance, 
the possibility of new mutations with different significance that are still to be 
identified, and the role of environmental factors in cancerogenesis and tumor 
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progression. Furthermore, preventive and interventional measures are still being 
developed and genetic testing carries potentially negative psychosocial 
repercussions for individual carriers and their families. Knowledge about the 
ethical and juridical implications of genetic testing is becoming essential for 
oncologists, who are being asked with increasing frequency to counsel their 
patients with respect to the medical, psychological and social repercussions of 
genetic information, even when obtained outside the context of an established 
patient-doctor relationship. Many articles and reviews have addressed the main 
ethical and social implications of BRCA testing (Surbone 2011), including 
informed consent, privacy and confidentiality, a person’s right wheter or not to 
know their genetic information, carriers’ responsibility to share genetic 
information with relatives at risk,  reproductive choices based on preimplantation 
diagnosis, appropriate testing of children and adolescents, equitable access to 
testing, disposition of biological samples, and genetic discrimination.  
Indeed, genetic information refers to genetic testing for patients and/or for 
family members up to fourth-degree relatives. A genetic test is any analysis to 
detect genotypes, genetic mutations or chromosomal changes, not including 
analysis of proteins or metabolites directly related to a manifested disease. 
Genetic information also refers to any manifestation of disease or disorder in a 
family member, and/or to the participation of a person or family member in 
research that involves genetic testing, counseling or education. 
Genetic information thus has unique aspects with respect to other medical 
information, as it carries potential value, but also danger, for individuals other 
than the person tested. Beyond the ethical and legal implications of genetic 
testing, experts and the public have expressed different views on the value of 
BRCA testing, from stressing the importance of genetic knowledge for high-risk 
women as a means to enhance control of their lives, to worrying about the 
potentially negative repercussions of genetic information.  
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5. CONCLUSIONS  
 
In recent years the spectrum of cancer-related genes has widened 
considerably. The potential of new sequencing technologies, from whole genome 
to exome sequencing, can accelerate the discovery of new susceptibility genes, 
not only for breast cancer, but also for other types of cancer. Targeted capture and 
massively parallel sequencing of specific genes can successfully identify families 
at risk for developing breast and/or ovarian cancer; now it seems that this 
technique is ready to be applied in a clinical setting. Knowing the genetic defect 
responsible for cancer-predisposition in at risk families can pave the way to 
customized, targeted therapies with extremely beneficial results. Increasing 
evidences indicate that knowledge of the BRCA1 and BRCA2 mutation status will 
enable a patient and her/his health care provider to make informed decisions about 
cancer prevention, screening and treatment. To date, there is a compelling 
evidence of the efficancy of the surgical prevention of hereditary breast and 
ovarian cancer, through mastectomy and oophorectomy; however, further studies 
need to be performed on chemoprevention and on individualized therapy for 
women with BC and a BRCA1 or BRCA2 mutation. Nevertheless, genetic 
counseling for these genes can be complicated.  
The above NGS mentioned method allowed the discovery of 
BRCA1/BRCA2 mutations not only in BC affected subjects but also in their 
relatives, in order to improve prevention and treatment of BRCA-mutation 
carriers. In addition, functional studies performed on novel variants, and ones that 
will be performed in the future, will contribute to improve the knowledge about 
HBOC genetics and to make medical decisions: indeed, a variant considered 
deleterious will be treated differently, and more safety, from a VUS that remains 
of uncertain significance and difficult to approach.  
Therefore, based on these findings the future aims of this work are to 
enlarge the number of women enrolled for BRCA1/BRCA2 screening in order to 
improve and increase the prevention of BC. This increase of prevention must be 
done especially in young women and before the disease onset, but also in men 
who in the past were wrongly considered not at risk to develop BC or other 
malignancies connected to BRCA mutations. The study proposes, on one hand, to 
include known causative mutation-carriers in clinical studies, and on the other 
hand to build panels of disease-related genes for NGS. Indeed, one of the future 
aims of this work will be to screen negative BRCA breast cancer patients with a 
strong family history of cancers, using large panels of cancer-related genes, 
through Illumina sequencing technologies. This second level screening will be 
useful to find other BC-related genes and to improve the knowledge about HBOC 
genetics.  
Finally, the methods described in this study will open new aspects of 
cancer knowledge and management, not only to improve early BC diagnosis but 
especially to direct therapies to “personalized” medicine. 
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